Novel interaction partners of the chromatin remodeler CHD7, a protein mutated in CHARGE syndrome by Batsukh, Tserendulam
  
 
 
Novel interaction partners of the chromatin 
remodeler CHD7, a protein mutated in CHARGE 
syndrome 
 
 
                                               
Dissertation 
zur Erlangung des Doktorgrades 
der Mathematisch-Naturwissenschaftlichen Fakultäten 
der Georg-August-Universität zu Göttingen 
 
 
 
vorgelegt von 
Tserendulam Batsukh 
aus Ulaanbaatar, Mongolei 
 
Göttingen, 2012 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D7 
 
Referent: Prof. Dr. Dr. Wolfgang Engel 
Korreferent: Prof. Dr. Sigrid Hoyer-Fender 
Tag der mündlichen Prüfung:  
 
 
  
 
 
 
 
 
 
Dedicated to my family, 
                       whose love and supports were always present and encouraged me in my path. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of contents 
 
i 
 
Table of contents 
Table of Contents ........................................................................................................... ...........i 
List of Tables and Figures ........................................................................................................ii 
1. Zusammenfassung ................................................................................................. ...............1 
1. Summary...............................................................................................................................3 
2. Introduction ..........................................................................................................................5 
2.1 Chromodomain helicase DNA-binding family of chromatin remodelers………...5 
2.2 Function of CHD7.……………………………………………………………......7 
2.3 Role of CHDs in human diseases…………………………………………………9 
2.4 CHD7 and CHARGE syndrome……………………………………………........10 
3. Results .................................................................................................................. ..............14 
3.1 CHD8 interacts with CHD7, a protein which is mutated in CHARGE 
       Syndrome……………………………………………………………………......15 
3.2 Identification and characterization of FAM124B as a novel component  
       of a CHD7 and CHD8 containing complex…………………….………….........26 
4. Discussion ……………………………………………………………………….…..........51 
4.1 Known CHD7 complexes and function……………………………………….....51 
4.2 Known CHD8 complexes and function………………………………………….53 
4.3 CHD8 builds together with CHD7 a complex……………………………….......55 
4.4 Evaluating the effect of 4 CHD7 missense mutations on the interaction 
       between CHD8 and CHD7………………………………………………….......57 
4.5 FAM124B is associated with CHD7 and CHD8…………………………….......58 
4.6 Subcellular localization and expression profile of Fam124B in  
       comparison of Chd7 and Chd8………………………………….…………........59 
4.7 Structure and Function of FAM124B…………………………………………....63 
4.8 Future endeavors and perspectives……………………………………………....64 
5. References ..........................................................................................................................67 
6. Abbreviations .....................................................................................................................80 
7. Acknowledgments ..................................................................................................... .........83 
8. Curriculum Vitae ........................................................................................... .....................84 
9. List of Publications .................................................................................................. ...........85 
 
 
 
Table of contents 
 
ii 
 
List of Tables and Figures 
Figure 2.1. Mechanism for ATP-dependent chromatin remodeling………………………….5 
Figure 2.2. Structural domains of human CHD family of proteins ………………………… 6 
Table 2.1. Overview of the functions of the CHD family of proteins .....................................8 
Table 2.2. Human diseases associated with CHD proteins………………………………… 10 
Figure 2.3. Distribution of pathogenic mutation types in the CHD7 gene………………….12 
Figure 4.1. Models for CHD7complexes……………………………………………………53 
Figure 4.2. Models for CHD8 complexes…………………………………………………...55 
Figure 4.3. CHD7 and CHD8 endogenous interaction in HeLa cells shown by 
       the Duolink PLA method…………………………………...…………………..56 
Figure 4.4. Hypothetical Enhancer and Promoter interaction via CHD7 and CHD8 
       containing protein/transcription factors (TF) complex mediated 
       DNA-loop model………………………………………………………………..58 
Figure 4.5. Immunostaining Fam124B of adult brain shown in comparison with 
      Chd7 and Chd8…………………………………………………………………..60 
Figure 4.6. Chd7, Chd8 and Fam124B immunostainings on sagittal section of 
       an E12.5 wildtype embryo ………………………………………...…..……......61 
Figure 4.7. Chd7, Chd8 and Fam124B immunostaining on coronal section of 
       the E12.5 mouse embryo…………………………………………..……..……...62 
Figure 4.8. A homologous part of FAM124B protein alignment from Human to 
      Zebrafish by Constraint-based Multiple alignment tool……..…………………..64 
Figure 4.9. Effect of CHD7 knockdown on expression of transcription factor Twist 
      involved in neural crest formation……………………………………………….65 
 
 
 
 
 
 
 
 
 
 
Zusammenfassung  
 
1 
 
1. Zusammenfassung  
CHARGE Syndrom, ein autosomal dominant vererbtes Malformationssyndrom wird 
durch Mutationen im Chromodomänen Helikase DNA bindenden protein 7 (CHD7) Gen 
hervorgerufen. In 10% der „typischen“ und 40-50% der „atypischen“ CHARGE Patienten 
findet sich keine Mutation im CHD7 Gen und somit bleibt die Ursache der Symptomatik in 
diesen Fällen unklar. CHD7 ist ein nukleär lokalisierter chromatin remodeler, der in großen 
Multiproteinkomplexen detektiert werden konnte und die Expression verschiedener Gene 
reguliert. Die Charakterisierung von CHD7 Interaktionspartnern ist möglicherweise hilfreich 
um die Pathogenese des CHARGE Syndroms zu verstehen. Für einige andere genetisch 
bedingte Erkrankungen konnte gezeigt werden, dass Mutationen in Interaktionspartnern zu 
demselben oder einem ähnlichen Krankheitsbild führen. Daher vermuten wir, dass CHD7 
Interaktionspartner gute Kandidaten sind, die möglicherweise im mutierten Zustand ebenfalls 
zum CHARGE Syndrom führen. 
Im ersten Teil dieser Arbeit wurde CHD8 als ein Interaktionspartner von CHD7 
identifiziert. Die Interaktion des CHD7 Teilstückes (Aminosäuren: 1593-2178) mit einem 
CHD8 Teilstück (Aminosäuren: 1789-2302) wurde mittels verschiedener molekularer 
Techniken validiert. Zusätzlich konnten wir zeigen, dass die Interaktion im Nuckleoplasma 
stattfindet. Darüber hinaus wurde der Einfluss von 3 in der Literatur beschriebenen Mutationen 
(p.His2096Arg, p.Val2102Ile und p.Gly2108Arg) und einer neu identifizierten (p.Trp2091Arg) 
CHD7 missense Mutation auf die CHD7-CHD8 Interaktion mittels Yeast two hybrid (Y2H) 
und Co-Immunopräzipitation (Co-IP) untersucht. Während wir mittels Y2H zeigen konnten, 
dass die CHD7-CHD8 Interaktion durch die CHD7 missense Mutationen p.Trp2091Arg, 
p.His2096Arg und p.Gly2108Arg aufgehoben wird, konnte dieser Effekt mittels Co-IP nicht 
nachgewiesen werden. Daher vermuten wir, dass CHD7 und CHD8 einerseits direkt 
miteinander interagieren (gezeigt durch die direkten Y2H Experimente) und zusätzlich indirekt 
über sog. Linker Proteine, die zusammen mit CHD7 und CHD8 einen großen Proteinkomplex 
formen (Erklärung für die Co-IP Ergebnisse). Zusätzlich haben wir CHD7 negative CHARGE  
Patienten auf Mutationen im CHD8 Gen untersucht. 
Im zweiten Teil der Doktorarbeit zeigen wir die Ergebnisse der SILAC und 
Massenspektrometrie Analyse, bei der wir das bisher uncharakterisierte Protein FAM124B als 
eine Komponente eines CHD7-CHD8 enthaltenden Komplexes identifizierten. Die Interaktion 
mit dem CHD8 Teilstück (Aminosäuren 1789-2302) wurde mittels direktem Y2H und Co-IPs 
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validiert, während eine Interaktion mit dem CHD7 Teilstück (Aminosäuren 1593-2178) nur 
mittels Co-IP bestätigt werden konnte, wodurch gezeigt wurde, dass FAM124B nicht direkt 
mit der o.g. CHD7 Region interagiert. Zusätzlich erfolgte eine Charakterisierung von 
FAM124B. Wir konnten zeigen, dass FAM124B, wie CHD7 und CHD8 im Zellkern lokalisiert 
ist. Fam124B wird bei der Maus in den Organen, die beim CHARGE Syndrom betroffen sind 
expremiert. Eine starke Expression konnte in dem sich entwickelnden Gehirn, Herzen, Lunge 
und im Rückenmark von E12.5 Mauseembryonen nachgewiesen werden. Kürzlich konnte 
gezeigt werden, dass Mutationen in CHD8 Autismus (ASD) und Entwicklungsstörungen des 
Nervensystems (NDD) bewirken können. Zusammenfassend, weisen unsere Daten darauf hin, 
dass das bisher uncharakterisierte Protein FAM124B eine sehr wichtige Funktion in der 
Embryonalentwicklung hat und möglicherweise an der Pathogenese des CHARGE Syndroms 
und ASD/NDD beteiligt ist. 
Um eine mögliche Rolle von FAM124B an der Pathogenese des CHARGE Syndroms und 
Neurocristopathien  zu analysieren, planen wir die Herrunterregulierung von Fam124B in 
Xenopus laevis um anschließend den Einfluss von Fam124B auf Gene, die an der 
Neuralleistenzellformation beteiligt sind zu testen. Die Generierung eines Fam124B knockout 
Mausmodels und die weitere Charakterisierung von CHD7 Interaktionspartnern werden zur 
Erlangung tiefgreifender Kenntnisse des molekularen Mechanismus des CHARGE Syndroms 
und Autismus Erkrankungen hilfreich sein. 
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1. Summary 
CHARGE syndrome, an autosomal dominant inherited multiple malformation syndrome is 
caused by mutations in the chromodomain helicase DNA binding protein 7 gene (CHD7). In 
10% of ‘typical’ CHARGE patients and 40-50% of ‘atypical’ CHARGE patients no mutation 
in the CHD7 gene is detectable and therefore the molecular cause is still unknown. CHD7 is a 
nuclear chromatin remodeling protein found in big protein complexes and regulating gene 
expression of various genes. We suggested that the characterization of CHD7 interacting 
partners can be useful for understanding the pathogenesis of CHARGE syndrome. 
Furthermore, for other genetic diseases it was shown that mutations in interacting partners lead 
to the same or a similar phenotype. Therefore, we hypothesized that CHD7 interacting partners 
are good candidates, leading to CHARGE syndrome when they are mutated. 
In the first part of the thesis, CHD8 was identified as an interacting partner of CHD7. The 
interaction of the CHD7 part (1593 – 2178aa) with the CHD8 part (1789 – 2302aa) was 
validated by different molecular techniques.  Additionally, we could show that the interaction 
takes place in the nucleoplasm. Furthermore, the influence of 3 known (p.His2096Arg, 
p.Val2102Ile and p.Gly2108Arg) and one (p.Trp2091Arg) newly identified CHD7 missense 
mutation on the CHD7-CHD8 interaction was elucidated by direct Yeast two hybrid (Y2H) 
and co-immunoprecipitation (Co-IP) methods. By Y2H we could demonstrate that the 
missense mutations p.Trp2091Arg, p.His2096Arg and p.Gly2108Arg disrupt the CHD7-CHD8 
interaction, while no influence on the interaction could be seen in Co-IP assays. Therefore, we 
suggest that CHD7 and CHD8 interact directly (shown by Y2H) and indirectly via additional 
linker proteins which build together with CHD7 and CHD8 a large protein complex 
(explaining the Co-IP result). In addition, we reported about the sequence analysis of the 
CHD8 gene in CHD7 mutation negative patients with CHARGE syndrome. 
 In the second part of the thesis, we showed the results of a SILAC and mass-spectrometry 
approach that identified the hitherto unknown protein FAM124B as a member of CHD7-CHD8 
containing complex. The interaction with the CHD8 part (1789 – 2302aa) was validated by 
direct Y2H and Co-IP methods whereas the interaction with the CHD7 part (1593 – 2178aa) 
could be only confirmed with the Co-IP assay, demonstrating that FAM124B interacts not 
directly with the analyzed CHD7 region. Furthermore, we characterized FAM124B. We could 
show that FAM124B is localized in the nucleoplasm like CHD7 and CHD8. Murine Fam124B 
is expressed in the organs affected in CHARGE syndrome. High expression could be observed 
in the developing brain, heart, lung and spinal cord of E12.5 mouse embryos. Recently, CHD8 
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mutations are shown to be a cause of autism spectrum disorders (ASD) as well as 
neurodevelopmental disorders (NDD). In conclusion, our results indicate that the hitherto 
uncharacterized protein FAM124B might be very important for embryonic development and 
could be involved in the pathogenesis of CHARGE syndrome and ASD/NDDs. 
Moreover, to analyse the possible role of FAM124B in the pathogenesis of CHARGE and 
neurocristopathies, we plan to perform a knockdown of FAM124B in Xenopus laevis and test 
its influence on genes related to neural crest formation. Generation of a knockout mouse model 
for Fam124B and further characterization of the CHD7 interacting complex members will help 
to learn more about the molecular mechanism behind CHARGE syndrome and ASD/NDDs. 
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2.  Introduction 
2.1 Chromodomain helicase DNA-binding family of chromatin remodelers 
Chromatin is a DNA-protein complex offering the possibility to package large amounts of 
DNA into the small area of the nucleus by wrapping the DNA.  The basic unit of the chromatin 
assembly is called nucleosome that consists of eight histone proteins (Ho & Crabtree 2010). 
Depending on the chromatin condensation grade (loosely or tightly packed DNA), the 
transcription of a certain gene is possible or not, because transcription factors and RNA-
polymerases need free access to their binding sites. Therefore, the condensation of DNA 
provides an important mechanism to regulate gene expression in living cells (Wolffe 1992, 
Hall & Georgel 2007).  Chromatin remodelers can alter the structure of chromatin by different 
mechanisms: nucleosome sliding, histone exchange, nucleosome eviction and alteration of the 
nucleosome structure (Wolffe 1992, Allis et al. Epigenetics 2007, Hall & Georgel 2007) (Fig. 
2.1). 
              
Figure 2.1. Mechanism for ATP-dependent chromatin remodeling. Different chromatin remodeling 
models are described by showing the change in position or composition of nucleosomes relative to the DNA 
wrapped around it. The central panel indicates a starting chromatin region where linker DNA is indicated in 
yellow and nucleosomal DNA in red. a: nucleosome sliding movement along the DNA, b: exchange of a variant 
histone for a standard histone to create a variant nucleosome, c: eviction of nucleosomes to open a large region of 
DNA. This mechanism might depend on other proteins, such as histone chaperones or DNA-binding factors, in 
addition of remodeling proteins, d: creating a loop on the surface of the nucleosome (Adapted and modified from 
Allis et al. Epigenetics 2007). 
B 
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Several chromatin remodeling complexes are known. The Chromodomain Helicase DNA 
binding (CHD) gene family belongs to the group of ATP-dependent chromatin remodelers (Ho 
& Crabtree 2010). In human, the CHD family consists of 9 members. All of them share the 
unique combination of two chromodomains (chromatin organization modifier) (Messmer et al. 
1992), a sucrose non-fermenting (SNF2)-like helicase/ATPase domain and DNA-binding 
domains (Hall & Georgel 2007; Marfella & Imbalzano 2007) (Fig. 2.2).  
 
Figure 2.2. Structural domains of human CHD family of proteins. Full length protein sequences were 
analyzed by SMART program and modified. (http://smart.embl-heidelberg.de/). CHD1-2 (Subgroup I) have the 
simplest protein structure which is N-terminal 2 chromodomains, in the middle part a DEXDc helicase (DEAD 
like helicase), ATP-helicase (ATPase) domain and C-terminal a DNA-binding domain. CHD3-5 (Subgroup II) 
have in addition N-terminal double PHD (Plant homeo domain) domains followed by the chromodomains. CHD6-
9 (Subgroup III) proteins have in addition a C-terminal SANT domain followed by two BRK domains.   
The SNF2-like ATPase domain was found in many proteins which are involved in 
chromatin assembly, transcription regulation, DNA repair, DNA replication, development and 
differentiation (Tsukiyama 2002, Smith & Peterson 2005, de la Serna et al. 2006). 
Mutational analysis of helicase and chromodomains revealed their crucial role for proper 
binding with chromatin (Kelley et al. 1999). Detailed functional analysis of chromodomains 
led to the suggestion that they mediate chromatin interactions through the direct binding of 
DNA, RNA, and methylated histone H3 (Akhtar et al. 2000, Bouazoune et al. 2002, Fischle et 
al. 2003, Min et al. 2003, Brehm et al. 2004, Flanagan et al. 2005, Pray-Grant et al. 2005, Sims 
et al. 2005, Kim et al. 2006).   
Because of additional domains, the CHD family of protein members is further divided into 
3 subgroups (Hall & Georgel 2007, Marfella & Imbalzano 2007) (Fig. 2.2). CHD1 and CHD2 
belong to the first subgroup.  They have the simplest protein structure among the other family 
members consisting of 2 chromodomains, a SNF2-like helicase/ATPase domain and DNA-
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binding domains. Although the subgroup I members are highly homologous to one another, 
they are significantly divergent in the 3' region. 
The second subgroup contains CHD3, CHD4 and CHD5. They share in addition two N-
teminal PHD (plant homeo domain) zinc  finger domains (Sims & Wade 2011) which are 
known to be involved in special chromatin remodeling mechanisms (Eberharter et al. 2004, 
Ragvin et al. 2004) as well as in epigenetic processes by binding to methylated histone 
peptides (Pena et al. 2006, Shi et al. 2006).  
CHD6-9 belong to subgroup III. All subgroup III members have  two BRK domains 
(Brahma and Kismet domain) at C-terminus with unknown function, three conserved regions 
(CR1-3) with unknown function and a SANT domain (Switching-defective protein 3, Adaptor 
2, Nuclear receptor corepressor, Transcription factor IIIB) (Janssen et al. 2012). The SANT 
domain is suggested to act as a histone tail binding module (Boyer et al. 2004, Hall & Georgel 
2007) (Fig. 2.2). 
 
2.2 Function of CHD7 
Table 2.1 gives an overview of all human CHD family members and their possible or 
known functions in humans or other species as well as their existing mutant models. A more 
detailed description is given for the CHD7 gene. CHD7 is involved in transcriptional 
regulation (Schnetz et al. 2009) and mutations in this gene lead to CHARGE syndrome (see 
2.4) (Vissers et al. 2004). 
The CHD7 gene is located on chromosome 8q12.1 and consists of 38 exons with the ATG 
in exon 2 and the stop codon in exon 38. The genomic size is188kb and the gene encodes a 
protein with a predicted size of 336kDa (http://www.sciencegateway.org/tools/ 
proteinmw.htm). CHD7 is evolutionary highly conserved among species (orthologs were 
described in Xenopus, mouse, chicken, zebrafish, C.elegans and Drosophila melanogaster 
(Bosman et al. 2005, Aramaki et al. 2007, Shrinivasan et al. 2008, Bajpai et al. 2010).  CHD7 
expression is tissue and embryonic stage dependent and its expression pattern in human, 
mouse, chicken, zebrafish and in other species match with the developmental defects in 
CHARGE syndrome (Bosman et al. 2005, Lalani et al. 2006, Sanlaville et al. 2006, Aramaki et 
al. 2007). Since the discovery that CHD7 mutations lead to CHARGE syndrome in human, the 
CHD7 gene has been studied more functionally. Several animal models for CHARGE 
syndrome were created (Table 2.1) (Siebert et al. 1985, Bergman et al. 2005, Hurd et al. 2007, 
Bajpai et al. 2010, Schnetz el al. 2010, Zentner et al. 2010, Patten et al. 2012).  
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Table 2.1. Overview of the functions of the CHD family of proteins. 
Most of the malformations present in CHARGE patients have been observed in animal 
models of mouse, xenopus and zebrafish, e.g craniofacial malformations and heart defects etc 
Genes  Molecular functions Mutants phenotype and in vivo function 
CHD1 Transcriptional repressor. Interacts with SSRP1. 
Transcription elongation , Transcription activator 
(Gaspar-Maia A. et al. 2009) 
Maintenance of mouse embryonic stem cell. (Gaspar-
Maia A. et al. 2009) 
CHD2 Unknown Chd2 null mice embryos have growth retardation and die 
before birth, 
Decreased neonatal viability, non-neoblastic lesions 
(Marfella et al., 2006) 
CHD3 Component of Nurd complex ( Tong et al. 1998, Xue 
et al. 1998, Zong et al. 1998) 
Drosophila: Nucleosome-stimulated ATPase activity 
and mobilizes nucleosomes (Brehm et al. 2004) 
Transcriptional repression (Sims et al. 2003) 
Several deficient model system of CHD3 suggest that it 
has a role in transcription repression ( Kehle et al. 1998, 
Wade et al. 1998, Solari & Ahringer et al. 2000) 
CHD4 Component of Nurd complex ( Tong et al. 1998, Xue 
et al. 1998, Zong et al. 1998) 
Transcriptional repression (Sims et al. 2003) 
T-cell development, Lymphocyte differentiation 
(Williams et al. 2004) 
CHD5 Unknown  Potential tumor suppressor in breast, colon, and 
neuroectodermal cancers ( Sims and Wade 2011) 
CHD6 Localizes to sites of transcription and is induced by 
DNA damage (Jennifer et al. 2011) 
 
 
 
 
 
One patient with translocation t(18;20)(q21.1;q11.2)  has 
mild to moderate mental  retardation and minor facial 
anomalies, including a broad, square face, hypertelorism, 
flat nasal bridge, prominent ears, and a short neck. 
(Karlscheuer et al. 2008) 
CHD6 mutation in some transitional cell carcinoma (Gui 
et al. 2011) 
CHD7 CHD7 binds in a cell type and developmental stage 
specific manner to methylated histone H3K4 in 
enhancer region (Bergman et al. 2005) 
 
 
Transcriptional regulation of nuclear genes (Schnetz 
el al. 2010) 
 
Transcriptinal regulation of ribosomal RNA 
biogenesis in nucleolus.  Interacts through rDNA with 
treacle, the protein involved in Treacher Collins 
syndrome  (Zentner et al. 2010) 
 
Fine tuning effect on ES specific genes in mutant null 
mouse ESCs. Chd7 colocalizes with ES cell master 
regulators Oct4, Sox2 and Nanog. (Schnetz el al. 
2010) 
Whirligig Chd7 null mouse embryo dies at E10.5. 
Heterozygous mice shows head bobbing and circling 
behavior due to inner ear defect, heart malformations, 
cleft palate, choanala atresia, genital anomalies etc. 
(Bergman et al. 2005, Bosman et al. 2010) 
 
Homozygous Chd7 gene trap mutant mice die pränatally. 
Heterozygous  associated with defects in multiple 
developing tissues (Hurd et al. 2007) 
 
Xenopus and human neural crest cell study showed it is 
essential role for formation of multipotent migratory 
neural stem cells. 
Chd7 is required for the organization of the neural retina 
in zebrafish. Knockdown of Chd7 display an abnormal 
organization of motor neurons and severe loss of the 
facial nerves  (Siebert et al. 1985, Bajpai et al. 2010, 
Patten et al. 2012) 
CHD8 CTCF-CHD8 has a role in insulation and epigenetic 
regulation at active insulator sites. (Ishihara et al. 
2006) 
CHD8 regulates HOXA2 gene expression negatively 
(Yates et al. 2010) 
Coregulator of androgen-responsive transcription 
(Menon et al. 2010) 
Xenopus: Duplin regulates Wnt signalling negatively 
by binding beta-cathenin (Sacomoto et al. 2010) 
CHD8 regulates beta-cathenin targeted genes 
negatively. CHD8 interacts with the WAR complex 
members (Thompson  et al. 2008) 
 
Duplin knockout mice show early embryonic lethality 
and growth retardation (Nishiyama et al. 2004) 
 
CHD9 It might be involved in differentiation of osteogenic 
cells (Shur and Benayahu. 2005, Shur et al. 2006) 
 
Introduction  
 
9 
 
(Bosman et al. 2005, Adams et al. 2007, Hurd et al. 2007, Cleary et al. 2009, Layman et al. 
2009, Randall et al. 2009, Bajpai et al. 2010, Bergman et al. 2010, Jacobs-McDaniels & 
Albertson 2011, Layman et al. 2011, Patten et al. 2012).  Recent functional studies could show 
that CHD7 binding sites have features of enhancer elements (Heintzman et al. 2009). Indeed, a 
comparative gene expression study in embryonic stem cells (ESCs) derived from wild type, 
heterozygous and homozygous CHD7 mutant mice demonstrated that CHD7 binds 
predominantly to methylated histone H3K4 in enhancer elements and regulates genes in a cell 
type and stage specific manner (Schnetz et al. 2009, 2010).  
Kismet is the ortholog of CHD supgroup III (CHD6-9) members in Drosophila. Srinivasan 
et al. (2008) studied Kismet and could demonstrate that it regulates gene transcription by 
recruiting the ASH1 (Absent, Small or Homeotic 1) and TRX (Trithorax) histone 
methyltransferases to chromatin.  
In addition, a Chd7 knockdown in Xenopus multipotent migratory neural crest cells 
revealed that crucial transcription factors like Sox2, Slug, and Twist are diminished. Therefore, 
the authors suggest an important role for CHD7 in gene expression programs for neural crest 
cell migration and specification (Bajpai et al. 2010). However, a recent study of Randall et al. 
(2009) demonstrated that a Chd7 rescue in only neural crest cells cannot correct the phenotype 
of pharyngeal arch defects, while a Chd7 rescue in both neural crest cells and in ectoderm 
could do it. These findings demonstrate the necessity of CHD7 expression in ectoderm.  
 
2.3. Role of CHDs in human diseases 
To date, CHD3, CHD4, CHD5, CHD7 and CHD8 are known to be involved in human 
diseases (Table 2.2). In dermatomyositis, which is a connective tissue disease, CHD3 and 
CHD4 have been characterized as autoantigens in inflammation of both muscle and skin (Airio 
et al. 1995, Ge et al. 1995, Seelig et al. 1995, 1996). CHD3 is also suggested to play a role in 
the pathogenesis of Hodgkin’s lymphoma by interacting with Ki-1/57 (Lemos et al. 2003), an 
intracellular phosphoprotein which is a marker for malignant cells in Hodgkin’s lymphoma 
(Schwab et al. 1982, Rhode et al. 1992). 
CHD5 is found to be deleted in neuroblastoma and glioma cell lines (Thompson et al. 
2003, Law et al. 2005, White et al. 2005). Neuroblastoma is an embryonal malignancy of the 
sympathetic nervous system arising from neuroblasts. It frequently affects infants, usually 
under two years old (www.nhs.uk/conditions/Neuroblastoma/Pages/Introduction.aspx).  CHD5 
is located on chromosome 1p36.31. Deletions of 1p36 are common in human neuronal, 
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epithelial and hematopoietic cancers.  Bagchi et al. (2007) demonstrated that CHD5 acts as a 
tumor suppressor that controls proliferation, apoptosis, and senescence. 
Recent bioinformatic studies of Neale et al. (2011), O’Roak et al. (2012) and Talkowski et 
al. (2012) revealed chromosomal rearrangements, nonsense and missense mutations disrupting 
the CHD8 in patients with Autism Spectrum Disorders (ASD) and neurodevelopmental 
disorders (NDD), suggesting a role of CHD8 in the pathogenesis of these diseases (Neale et al. 
2011, O’Roak et al. 2012, Talkowski et al. 2012). 
 
CHD Protein Disease Reference 
CHD3  
 
 
 
CHD4 
 
CHD5  
 
 
CHD8 
 
CHD7 
Dermatomyositis  
 
Hodgkin's lymphoma  
 
Dermatomyositis 
 
Neuroblastoma  
 
 
Autism spectrum disorders and NDD 
 
CHARGE Syndrome 
 
Kallman syndrome, normosmic IHH 
Nilasena et al. 1995, Seelig et al. 1995, Seelig et al. 1996 
 
Schwab U et al. 1982 
 
Nilasena et al. 1995, Seelig et al. 1995, Seelig et al. 1996 
 
Thompson et al. 2003, Law et al. 2005, White et al. 2005 
Bagchi et al 2007 
 
Neale et al. 2011, Talkowski et al. 2012, O’Roak et al. 2012 
 
Visser et al. 2004, Williams et al.2005 
 
Kim et al. 2008, Jongmans et al. 2009, Bergman et al. 2011a 
 
Table 2.2. Human diseases associated with CHD proteins (Adapted and modified from Marfella & Imbalzano 
2007). NDD = neurodevelopmental disorders, IHH = idiopathic hypogonadotropic hypogonadism. 
 
2.4 CHD7 and CHARGE syndrome 
CHARGE syndrome is an autosomal dominant inherited disease caused by heterozygous 
CHD7 mutations (Vissers et al. 2004). The name “CHARGE” is an acronym describing 
commonly occurring clinical symptoms like Coloboma, Heart malformation, Atresia of the 
choanae, Retardation of Growth and development and Genital anomalies (Pagon et al. 1981, 
Blake et al. 1998, Jongmans et al. 2006, Lalani et al. 2006, Bergman et al. 2011b). Additional 
symptoms like cleft lip/palate and tracheoesophageal fistula can occur, leading to a high 
variability in the clinical presentation of CHARGE syndrome patients. Therefore, diagnostic 
criteria were set up to help clinicians finding the right diagnosis. The currently used criteria for 
CHARGE syndrome were defined by Blake et al. (1998) and updated by Verloes in 2005.   
According to Blake et al. (1998), major criteria are: anomalies of ear (90-100% of patients 
with CHD7 mutation), ocular coloboma and/or microphthalmia (80-90%), cranial nerve 
dysfunction, swallowing and breathing difficulties (70-90%). Minor criteria according to Blake 
are: genital anomalies, developmental and growth retardation, congenital heart defects, cleft 
lip/palate, tracheoesophageal fistulas and facial dysmorphism (Horsch & Scheele 2011). If four 
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main or three main and three minor criteria are present, patients will be clinically diagnosed 
with CHARGE syndrome. In Verloes’s criteria (2005) eight key features are proposed, three 
major (coloboma, choanal atresia, semicircular canals anomalies) and five minors 
(rhombencephalic anomalies, hypothalamic-hypophyseal dysfunction, external/middle ear 
malformations, malformation of mediastinal viscera, and mental retardation). If 2/3 major 
elements and at least 3/5 minor traits are present, CHARGE can be diagnosed. Verloes also 
classified CHARGE ‘‘borderline phenotypes’’ in two groups: partial (or incomplete) 
CHARGE and atypical CHARGE. The diagnosis “partial CHARGE” get those patients who 
present 2 major and only 1 minor sign, whereas the diagnosis “atypical CHARGE” is given to 
those patients who have 2 major and no minor, or 1 major and at least 3 minor signs (Verloes 
2005). 
CHD7 mutations have been found also in patients with Kallman Syndrome (KS) (Table 
2.2) (Kim et al. 2008, Jongmans et al. 2009, Bergman et al. 2011a). Kallman syndrome is a 
clinically and genetically heterogenous disease which combines the absence of puberty 
(Hypogonadotropic Hypogonadism) with defective sense of smell (hyposmia or anosmia) 
(Dodé & Hardelin 2009). It is suggested that Kallmann syndrome is a mild variant of the 
phenotypic spectrum of CHARGE syndrome.  
Mutations in the CHD7 gene are distributed along the coding region, no mutation hotspots 
could be observed. Most frequent are nonsense and frameshift mutations (approximately 75% 
of all mutations) followed by missense and splice site mutations (20 % of all mutations). 
Complete and partial deletions/duplications and chromosomal rearrangements are rarely found 
in CHARGE syndrome patients (Fig. 2.3) (Janssen et al. 2012).  
But not in all clinically diagnosed patients with CHARGE syndrome mutations in the 
CHD7 gene were found (Jongmans et al. 2006, Lalani et al. 2006, Bergman et al. 2011a). 
Depending on different studies and which diagnostic criteria are used, the CHD7 mutation 
detection rate is in range of 33-100% for patients suspected of CHARGE syndrome and in 
average calculated as 58% (Vissers et al. 2004, Aramaki et al. 2006, Felix et al. 2006, 
Jongmans et al. 2006, Lalani et al. 2006, Sanlaville et al. 2006, Vuorela et al. 2007, Asakura et 
al. 2008, Wincent et al. 2008, Lee et al. 2009, Wessels et al. 2010). The average detection rate 
is much higher in patients diagnosed as “typical CHARGE syndrome patients”. For instance, 
Jongmans et al. (2006) found CHD7 mutations in more than 90% of patients who fulfilled the 
diagnostic criteria of Blake et al. (1998) and/or Verloes (2005). Therefore, in 10% of typical                         
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Figure 2.3. Distribution of pathogenic mutation types in the CHD7 gene. Nonsense and frameshift mutations 
are in over 75% of the patients with CHARGE syndrome. Missense and splice site mutations occur in 20%. 
Complete and partial deletions/duplications and chromosomal rearrangements happen rarely (Adapted from 
Janssen et al. 2012). 
 
CHARGE syndrome patients the molecular cause of the disease is unknown. Similar as in 
many other autosomal dominant diseases, also in CHARGE syndrome, genetic heterogeneity 
of more than one gene resulting in the disease is realized. For example, Noonan syndrome is 
caused by mutations in Ras/MAP kinase pathway genes such as PTPN11, SOS1, KRAS, RAF1, 
NRAS, BRAF or MAP2K1 (Tartaglia et al. 2001, Carta et al. 2006, Schubbert et al. 2006, Nava 
et al. 2007, Razzaque et al. 2007, Roberts et al. 2007, Zenker et al. 2007, Sarkozy et al. 2009, 
Cirstea et al. 2010), while Cornelia de Lange syndrome is caused by mutations in NIPBL, 
SMC1A and SMC3 (interaction partner of SMC1A) (Krantz et al. 2004, Tonkin et al. 2004, 
Musio et al. 2006, Deardorff et al. 2007).  
Therefore, we suggest genetic heterogeneity in CHARGE syndrome. Possibly, mutations 
in CHD7 interaction partners lead also to a CHARGE syndrome phenotype. Thus, aim of the 
study was: 
 to identify and characterize CHD7 interaction partners in order to understand the 
genetic basis behind CHARGE syndrome 
 Identification, validation and characterization of exact interacting area of CHD7 
and CHD8 
 What is the influence of some missense mutations of CHD7 to its’ interacting 
capacity to CHD8 
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 Identification of a novel interacting member of the CHD7-CHD8 complex by 
SILAC (Stable isotope labeling by amino acids in cell culture) and mass-spectrometry 
approach 
 Characterization of FAM124B protein, a novel hitherto unknown interacting 
member of CHD7 and CHD8 containing complex. 
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3. Results 
 
3.1 CHD8 interacts with CHD7, a protein which is mutated in CHARGE syndrome 
 
3.2 Identification and characterization of FAM124B as a novel component of a CHD7 and 
CHD8 containing complex 
 
 
Each chapter within the results starts with a brief description of the aims of the particular 
manuscript in context of the complete thesis, the status of the manuscript, and the author’s 
contribution to the work. 
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3.1 CHD8 interacts with CHD7, a protein which is mutated in CHARGE syndrome 
In this part of my thesis, we identified CHD8, another member of the CHD family of proteins, 
as an interaction partner of CHD7. CHD7 mutations are found in two-third of patients with 
CHARGE syndrome. Because of the information that some hereditary diseases are caused by 
alterations in several genes (genetic heterogeneity) of whom some of the gene products interact 
with each other, we studied interaction partners of CHD7. We used a part of CHD7 (amino 
acid 1593-2183) for a yeast two hybrid library screen and found CHD8 (amino acid 1789-
2091) as a potential interaction partner. The exact interacting area of both CHD proteins was 
identified by direct yeast two hybrid. The interaction of CHD7 and CHD8 was confirmed by 
direct yeast two-hybrid, co-immunoprecipitation and bimolecular fluorescence 
complementation assays.  Furthermore, we studied the influence of 3 known (p.His2096Arg, 
p.Val2102Ile and p.Gly2108Arg) and one newly identified missense mutation (p.Trp2091Arg) 
of the CHD7 gene on the CHD7 and CHD8 interaction. Therefore, we performed direct Y2H 
and CoIP experiments. Interestingly, the CHD7–CHD8 interaction was disrupted by the 
missense mutations p.Trp2091Arg, p.His2096Arg and p.Gly2108Arg in the direct Y2H 
experiment, while no influence on the CHD7-CHD8 binding capacity could be observed in Co-
IP studies. We explained the different findings of direct Yeast two hybrid and Co-IP results in 
that way that with Yeast two hybrid experiments a direct interaction between two proteins 
could be tested while Co-IPs cleaned up a whole complex and possible linker proteins can 
bridge the mutated area. In addition, twenty five CHD7 negative CHARGE patients were 
screened for CHD8 mutations. But no mutation could be detected in the candidate gene CHD8 
in our patients. As a result we hypothesized that CHD7 and CHD8 interact directly and 
indirectly via linker proteins. Further characterization of the complexes might help to better 
understand the pathogenesis of CHARGE syndrome. 
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3.2 Identification and characterization of FAM124B as a novel component of a CHD7 
and CHD8 containing complex 
Mutations in the chromodomain helicase DNA binding protein 7 gene (CHD7) lead to 
CHARGE syndrome, an autosomal dominant heterogeneous disorder. Earlier, we could show 
that a part of CHD7 interacts with a part of CHD8, another chromodomain helicase DNA 
binding protein which has been recently demonstrated to be involved in the pathogenesis of 
neurodevelopmental (NDD) and autism spectrum disorders (ASD). We searched for novel 
CHD7 and CHD8 interacting partners using stable isotope labeling by amino acids in cell 
culture (SILAC) in combination with mass spectrometry. As result we identified as a potential 
interaction partner of both CHD7 and CHD8 a new uncharacterized protein, named FAM124B 
(Family with sequence similarity 124B). Furthermore, the confirmation of the SILAC results 
by co-immunoprecipitation and yeast two hybrid experiments demonstrated that FAM124B is 
a potential novel component of a CHD7 and CHD8 containing complex. Interestingly, our 
studies of Fam124B expression in E12.5 mouse embryos and in adult mouse brain show an 
overlap of the Fam124B expression with the expression patterns of Chd7 and Chd8. Therefore 
we conclude that Fam124B is a novel protein possibly involved in the pathogenesis of 
CHARGE syndrome and neurodevelopmental disorders.  
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ABSTRACT 
Background: Mutations in the chromodomain helicase DNA binding protein 7 gene (CHD7) 
lead to CHARGE syndrome, an autosomal dominant multiple malformation disorder. Proteins 
involved in chromatin remodeling typically act in multiprotein complexes. We could 
previously demonstrate that a part of human CHD7 interacts with a part of human CHD8, 
another chromodomain helicase DNA binding protein presumably being involved in the 
pathogenesis of neurodevelopmental (NDD) and autism spectrum disorders (ASD). Because 
identification of novel CHD7 and CHD8 interacting partners will provide further insights into 
the pathogenesis of CHARGE syndrome and ASD/NDD, we searched for additional associated 
polypeptides using the method of stable isotope labeling by amino acids in cell culture 
(SILAC) in combination with mass spectrometry. 
 
Principle findings: The hitherto uncharacterized FAM124B (Family with sequence similarity 
124B) was identified as a potential interaction partner of both CHD7 and CHD8. We 
confirmed the result by co-immunoprecipitation studies and showed by direct yeast two hybrid 
experiments a direct binding to the CHD8 part. Furthermore, we characterized FAM124B as a 
mainly nuclear localized protein with a widespread expression in embryonic and adult mouse 
tissues.  
 
Conclusion: Our results demonstrate that FAM124B is a potential interacting partner of a 
CHD7 and CHD8 containing complex. From the overlapping expression pattern between Chd7 
and Fam124B at murine embryonic day E12.5 and the high expression of Fam124B in the 
developing mouse brain, we conclude that Fam124B is a novel protein possibly involved in the 
pathogenesis of CHARGE syndrome and neurodevelopmental disorders.  
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INTRODUCTION 
In humans, CHD7 (NM _017780) is one of nine members of the chromodomain helicase DNA 
binding domain (CHD) family that plays a role in controlling gene expression by ATP-
dependent chromatin remodeling. Mutations in the CHD7 gene are the major cause of 
CHARGE syndrome (OMIM 214800), an autosomal dominant congenital malformation 
disorder characterized by the combination of eye, ear, craniofacial structure, and heart defects 
[1-6]. However, in 5-10% of patients with a typical presentation of CHARGE syndrome and in 
40-60% of patients with an atypical presentation the underlying cause of the symptoms 
remains unclear [7]. For other autosomal dominant disorders, e.g. Noonan syndrome, a genetic 
heterogeneity is known, wherein mutations in different genes lead to a near similar phenotype. 
Therefore, we suggest that also in CHARGE syndrome mutations in one or more unknown 
genes are involved in the pathogenesis of this disease. 
Proteins involved in chromatin remodeling are typically found in multiprotein complexes. In 
recent and earlier studies different CHD7 interacting partners have been described [8-13]. In 
human neural crest-like cells CHD7 was shown to be associated with components of the BAF- 
(Brahma associated factor complex) and PBAF - complexes (Polybromo containing complex) 
[10]. Both belong to the SWI/SNF-family of ATP-dependent chromatin remodeling complexes 
and can act as transcriptional activators or repressors [14]. In murine embryonic stem (ES) 
cells a co-localization between Chd7 and the proteins p300, Oct4, Sox2, Nanog, Smad1 and 
Stat3 at enhancer elements was shown [9] leading to the hypothesis that these proteins are 
cofactors in enhancer promoter interactions [9]. CHD7 was also found to be associated with 
treacle, the protein that is involved in the pathogenesis of Treacher Collins syndrome [12]. 
These studies demonstrate that there are numerous CHD7 interacting partners, leading to the 
suggestion that there are cell type specific compositions of CHD7 containing complexes and 
that the subunits may change during development [7]. 
Recently, we could demonstrate that a part of the human CHD7 protein interacts with a part of 
the CHD8 protein, another CHD family member. Studies in Drosophila melanogaster 
demonstrated that kismet is the only gene related to the human subgroup III members (CHD6-
CHD9). Kismet has a functional role in transcriptional regulation by promoting early 
elongation by RNA Polymerase II as well as by recruiting the histone methyltransferases 
ASH1 and TRX to chromatin [15]. Rodriguez-Paredes et al. suggested that in mammals the 
function of kismet is overtaken by several subgroup III members (CHD6-CHD9) [16] and we 
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hypothesized that CHD7 and CHD8 build a core component of a complex with similar 
functions such as kismet [11]. CHD8 was found to be associated with the WAR complex [17]. 
This complex includes WDR5, ASH2L and RbBP5 (WAR) and is known as a subcomplex of 
mixed lineage leukemia (MLL) complexes, the Drosophila homolog to TRX complexes. The 
MLL complexes act as histone H3 Lys-4 methyltransferases [18].  
Furthermore, CHD8 binds directly beta-catenin and regulates negatively beta-catenin-targeted 
gene expression [17]. Microdeletions, chromosomal rearrangements disrupting CHD8 as well 
as de novo missense and nonsense mutations in the CHD8 gene were described in autism 
spectrum (ASD) and in neurodevelopmental (NDD) disorder patients, indicating that 
alterations in CHD8 can contribute to ASD and NDD [19-22].  
Identification of novel CHD7 and CHD8 interacting partners will provide further insights into 
the pathogenesis of CHARGE syndrome and ASD/NDD. Therefore, we tried to detect new 
binding partners by using the method of stable isotope labeling by amino acids in cell culture 
(SILAC) in combination with mass spectrometry. We identified FAM124B (Family with 
sequence similarity 124B) as a potential interaction partner of both CHD7 and CHD8. 
Additionally, we confirmed the interaction by co-immunoprecipitation and performed direct 
yeast two hybrid experiments. Furthermore, we examined the intracellular localization and 
tissue-specific expression of Fam124B during mouse embryogenesis and in adult mouse 
tissues. 
RESULTS 
Identification of FAM124B as part of the CHD7 and CHD8 interactomes 
In order to identify novel CHD7 and CHD8 interaction partners we applied stable isotope 
labeling by amino acids in cell culture (SILAC) in combination with mass spectrometry 
[23,24] (Figure 1). To achieve differential isotope labeling of HeLa cells, one cell batch was 
cultured in the presence of lysine and arginine containing light (L) isotopes of carbon and 
nitrogen (
12
C and 
14
N, L-lysine and L-arginine) while the other batch was cultured in the 
presence of lysine and arginine containing heavy (H) isotopes of carbon and nitrogen 
(
13
C6
15
N2-lysine and 
13
C6
15
N4-arginine). Accordingly, the two culture conditions confer distinct 
molecular masses on the cellular proteins and in this way proteins derived from SILAC-labeled 
cells can be distinguished and thus attributed to the L- or H-labeled cell batch by mass 
spectrometry. For elucidation of the CHD7- or CHD8 interactomes, the H-labeled cells were 
firstly co-transfected with the plasmids CHD7-CR1-3-pCMV-HA (containing amino acids 
1593 - 2178, NP_060250.2, in fusion with an HA-tag) and CHD8-pCMV-cmyc (spanning 
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amino acids 1789 – 2302, NP_065971.2, in fusion with an cmyc-tag). 24 hours post 
transfection, expression of the tagged proteins was confirmed by western blotting. 
Subsequently the respective H-labeled cells were lysed and the CHD7 part was purified by 
anti-HA immunoprecipitation. As a negative control the same immunoprecipitation was 
performed in lysates of non-transfected L-labeled HeLa cells. The purified proteins from both 
the H- and L-states were then pooled in equimolar amounts and subsequently digested with the 
endoproteinase trypsin. Derived peptides were identified by liquid-chromatography (LC)-
coupled tandem mass spectrometry (MS/MS), allocated to the corresponding proteins by 
database search and finally quantified using the MaxQuant software. An at least five-fold 
enrichment of heavy versus light peptides was considered to mark proteins that were 
specifically co-purified with the HA-tagged CHD7 part. The same experimental workflow was 
also performed with inverse labeling. In at least three biological replicates FAM124B was co-
purified with CHD7 and CHD8, which identifies this so far uncharacterized protein as a novel 
effector of the CHD7/8 interactome (Table S1-S3). 
Full length cloning and transcript analysis of FAM124B 
Information of the genomic and cDNA structure of FAM124B was obtained from NCBI 
database. In humans, two transcript variants are described. Transcript variant 1 contains two 
exons with the ATG in exon one and the stop codon in exon 2 resulting in a protein with 455 
amino acids (NP_001116251.1). Transcript variant 2 contains an alternate exon with an in-
frame stop codon leading to a shorter protein product with 272 amino acids (NP_079061.2). In 
mice, one transcript homologous to the human transcript variant 1 containing 456 amino acids 
was described (NP_775601.1). We validated the information by full length cloning and 
sequencing of human and mouse cDNAs derived from HeLa cells and mouse adult brain 
tissue, respectively.  
FAM124B co-immunoprecipitates with a part of CHD7 and a part of CHD8  
Co-Immunoprecipitation studies on HeLa cells were performed to confirm the CHD7-CHD8- 
FAM124B interaction. HeLa cells were co-transfected with either the CHD7-CR1-3-pCMV-
HA (amino acids 1593 - 2178, NP_060250.2) plasmid and FAM124B-1,3-pCMV-cmyc 
(transcript variant 1, NP_001116251.1) or with CHD8-pCMV-cmyc (amino acids 1789 - 
2302, NP_065971.2) and FAM124B-1,3-pCMV-HA (transcript variant 1, NP_001116251.1). 
Total protein was isolated after 24 hours. Immunoprecipitation with either the anti-CHD7 
(abcam, ab31824) or the anti-CHD8 antibody (abcam, ab84527) and detection with either the 
anti-cmyc (abcam, ab9106) or anti-HA antibody (Roche) lead to an approximately 51 kDa 
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band corresponding to the estimated size of FAM124B transcript variant 1 (Figure 2A). 
Reciprocal immunoprecipitation with anti-cmyc antibody and detection with the anti-CHD7 
antibody demonstrated a specific band of ~ 70 kDa, the estimated size for the CHD7 part 
fused to the HA-tag (Figure 2B). Using the anti-HA-antibody for precipitation, we detected a 
~ 68 kDa band corresponding to the estimated size of the CHD8 part fused to the cmyc tag 
(Figure 2C) by using the anti-CHD8 antibody. 
The same experimental procedure was then performed with the plasmid FAM124B-1,2-
pCMV-HA (transcript variant 2, NP_079061.2). Similar to the results for the FAM124B 
transcript variant 1, we could demonstrate an interaction with the CHD7 and CHD8 part with 
FAM124B transcript variant 2 (Figure 2D-F).  
 
FAM124B interacts directly with a part of CHD8 
Y2H experiments were performed to determine a direct interaction between CHD7, CHD8 and 
both variants of FAM124B using the following plasmids: FAM124B-1,3-pGADT7 (full 
lengths transcript variant 1), FAM124B-1,2-pGADT7 (full lengths transcript variant 2), 
CHD7-CR1-3-pGBKT7 (amino acids 1591-2181, NP_060250.2) and CHD8-pGBKT7 (amino 
acids 1789–2302, NP_065971.2). The yeast two hybrid experiments revealed that both 
transcripts of FAM124B directly interact with the CHD8 part, while no direct interaction with 
the CHD7 part, spanning the amino acids 1591-2181, could be observed (Figure 3). Because 
FAM124B transcript variants 1 and 2 have in common exon 1, we hypothesized that the 
FAM124B-CHD8 interacting area is located within exon 1 of FAM124B. 
Subcellular localization of FAM124B in HeLa cells 
To determine the subcellular localization of endogenous FAM124B in HeLa cells, we 
performed immunofluorescence staining by using a rabbit anti-FAM124B antibody 
(ProteinTech). FAM124B is localized mainly in the nucleus (Figure 4A). To test the specificity 
of the polyclonal anti-FAM124B antibody, we transiently transfected HeLa cells with either 
the plasmid FAM124B-1,3-pCMV-HA or the FAM124B-1,3-pCMV-cmyc to overexpress 
hemagglutinin (HA) or cmyc epitope tagged FAM124B-1,3 (transcript variant 1, 
NP_001116251.1). By using the rabbit anti-FAM124B antibody, the overexpressed protein 
was detectable mainly in the nucleus at an exposure time of 200 msec. By raising the exposure 
time to 2 sec, overexpressed and endogenous FAM124B could be observed. 
Immunofluorescence staining of recombinant HA tagged FAM124B using the anti-HA 
antibody (Roche) or staining of the recombinant cmyc tagged FAM124B using the anti-cmyc-
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antibody (abcam, ab9106) confirmed the results that FAM124B is preferentially expressed in 
the nucleus and that the rabbit anti-Fam124B antibody is specific (Figure 4B, C).  
 
Tissue specific expression of murine Fam124B  
The expression pattern of murine Fam124B was studied by semiquantitative reverse 
transcription polymerase chain reaction (RT-PCR) on RNA of wild type CD1 mouse tissues 
and E9.5 and E12.5 embryos (Figure 5A). The RT-PCR results were validated by quantitative 
real-time PCR (qRT-PCR) in 3 biological and 3 technical replicates (data not shown). Relative 
mRNA expression levels were determined by using ΔCt values and were normalized to the 
housekeeping genes Gapdh, Hprt and Sdha. Although, quantitative RT-PCR shows a high 
variability of the Fam124B expression status in different animals, the semiquantitative RT-
PCR results could be confirmed, with highest expression rate in lung and lowest in liver. 
Immunohistochemical staining (IHC) performed on adult mouse tissues confirmed the 
semiquantitative and quantitative RT-PCR results (Figure 5B). Furthermore, we evaluated the 
expression level of Fam124B in sections of adult mouse brains. Immunohistochemical 
examination demonstrated an expression of Fam124B in different brain areas (Figure 6A). 
Fam124B is highly expressed in the cortex, the hippocampus subfields 1-3 (CA1-3), the 
dentate gyrus, the caudate putamen, and the cerebellum. In situ hybridization (ISH) of cortex 
and hippocampus sections with a full-length Fam124B RNA probe supported the results 
obtained by IHC (Figure 7A, B). 
To explore the expression pattern of Fam124B during mouse development, we extended our 
IHC studies to sections of E12.5 mouse embryos, the timepoint when organogenesis takes 
place. Similar to adult mouse tissues, Fam124B expression at E12.5 was observed in different 
inner organs, with lowest expression in liver tissue (Figure 8A-H). In the developing heart, 
high expression was detected particularly in the endothelial cells of the atrium and along the 
trabeculated endocardium of the ventricle, while no expression could be observed in blood 
cells (Figure 8D). At E12.5 when the developing lung is not yet divided into lobes, Fam124B 
expression could be observed in the stroma cells and in the epithelial cells of the segmental 
bronchi (Figure 8G). Furthermore, Fam124B was expressed in the developing cochlea and the 
surrounding tissue (Figure 8E) as well as in neural cells. The dorsal root ganglia and the 
precartilage condensation zones in the neural arch showed Fam124B expression, while 
Fam124B expression was significantly reduced in the cartilage (Figure 8B). High Fam124B 
expression could be found in the spinal cord (Figure 8F) and in the developing brain (Figure 
9). 
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DISCUSSION 
Loss of function mutations in CHD7 lead to CHARGE syndrome, a well known malformation 
syndrome affecting several organs and sensory systems. CHD7 regulates the transcription of 
tissues-specific target genes through the mechanism of ATP-dependent chromatin remodeling 
[7-9, 12]. Chromatin remodeling proteins are typically found in large multiprotein complexes. 
For CHD7 several tissues-specific interacting partners are described [9, 10, 12, 13]. Thus, it 
can be suggested that there are cell type and developmental stage specific compositions of 
CHD7 containing complexes. However, the precise complex compositions for each tissue are 
still unknown. In an earlier study, we could demonstrate that a part of human CHD7 interacts 
with a part of human CHD8 both directly and indirectly, via potential linker proteins [11]. Loss 
of function mutations in CHD8 as well as de novo missense mutations were described in 
autism spectrum (ASD) and neurodevelopmental (NDD) disorder patients [19-22]. 
Interestingly, Betancur and colleagues described autism spectrum disorders in about two thirds 
of children with CHARGE syndrome [25], which supports our hypothesis of a CHD7-CHD8 
containing complex regulating the same cell type specific target genes. 
The identification and characterization of associated factors of a CHD7-CHD8 containing 
complex might play an important role in understanding the pathophysiology of CHARGE 
syndrome and ASD/NDD. Therefore, to further characterize this complex and to identify 
additional associated polypeptides interacting with the recently described human CHD7 and 
CHD8 part, we used the method of stable isotope labeling by amino acids in cell culture 
(SILAC) in combination with mass spectrometry. As a result of three biological replicates we 
identified the hitherto uncharacterized protein FAM124B as a potential interacting partner. In 
humans, two FAM124B transcript variants are present, while in mice, only one transcript, 
homologous to the human transcript variant 1, exists. The interaction of both human 
FAM124B transcript variants with the CHD7 and CHD8 part was confirmed by co-
immunoprecipitation experiments. Direct yeast-two hybrid studies were performed to specify 
the FAM124B - CHD7 - CHD8 interaction areas. Both transcripts of human FAM124B 
interact directly with the CHD8 part containing the amino acids 1789–2302 (NP_065971.2), 
while the FAM124B - CHD7 interaction is an indirect interaction or the interacting area is 
outside of the used CHD7 part spanning amino acids 1591-2181 (NP_060250.2). The 
biological role of human FAM124B or its orthologs in P.troglodytes, C.lupus, B.taurus, 
R.norvegicus, M.musculus, G.gallus, D.rerio is still unknown. Bioinformatic analysis of the 
amino acid sequence failed to identify any known functional domain. To gain further insight 
into the biological role of FAM124B and its mouse ortholog, we examined the subcellular 
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localization and the expression pattern. Immunofluorescence microscopy indicates that 
endogenous FAM124B is localized mainly in the nucleoplasm. CHD8 is described as a nuclear 
localized protein [26]. Concerning CHD7, a dual localization in the nucleoplasm and in the 
nucleolus was observed [12]. Therefore, we suggest, that the interaction between FAM124B, 
CHD8 and CHD7 may take place in the nucleoplasm.  
We could detect Fam124B expression in various adult mouse tissues, with highest expression 
in lung and heart, followed by kidney, brain and testis, whereas it was lowest expressed in 
liver. No Fam124B expression could be observed in blood cells. In adult mouse brain sections, 
we demonstrated Fam124B expression in several areas. Within the brain, high expression 
levels were found in the stratum granulosum of the cortex, stratum granulosum and 
purkinjense of the cerebellum, thalamic nuclei, caudate putamen, and hippocampus. 
CHD8 expression was previously found in various adult mouse tissues including heart, brain, 
spleen, lung, liver, skeletal muscle, kidney, and testis [26]. CHD7 expression pattern was 
determined by semiquantitative RT-PCR on several adult tissues including retina, cornea, 
brain, skeletal muscle, heart, kidney and lung [1]. Accordingly to these previously described 
data we could observe an overlapping expression pattern between CHD7, Chd8 and Fam124B 
in adult mouse tissues. Because CHARGE syndrome is a developmental disorder and 
NDD/ASD are caused by abnormal brain development, we extended our Fam124B expression 
studies to embryonic tissues. The expression pattern of CHD7 during development has been 
studied in embryos of different mammalian species, before [4, 5, 27-29]. During mouse 
development, Chd7 was found to be expressed at E12.5 in a wide range of head tissues (several 
brain areas with highest expression in proximity to the ventricles, in the choroid plexus, 
developing olfactory epithelium, ganglia of the cranial nerves, otic and optic pits, and the 
developing inner ear) and several regions of the body (especially the dorsal root ganglia and 
lung epithelium, as well as stomach epithelium, kidney, and heart) [27]. Fam124B expression 
at E12.5 was found in a variety of embryonic tissues (e.g. several brain areas, spinal cord, 
dorsal root ganglia, developing cochlea and surrounding tissues, lung, heart, and kidney), as 
well. Similar to the results of adult mouse tissues, Fam124B expression at E12.5 correlated in 
many embryonic tissues with the Chd7 expression pattern, and therefore Fam124B was found 
to be expressed in organs affected in CHARGE syndrome. 
It has already been shown that CHD7 binds to methylated histone H3 lysine 4 (H3K4) at 
enhancer elements and modify cell type specific gene expression in a fine-tuning manner [8, 
9]. Schnetz and colleagues hypothesized that the binding of a CHD7 containing complex to 
enhancer elements may modulate the expression rate of target genes through enhancer-
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promotor interactions [8, 9]. In mouse ES cells, a subset of Chd7 sites colocalize with p300, 
Oct4, Sox2 and Nanog. The subset of Chd7 sites, which are not co-occupied by these proteins, 
can also enhance transcription [9]. However, the associated factors of these Chd7 sites are still 
unknown. Possibly, the newly identified Fam124B may serve as an associated factor involved 
in Chd7 enhancer-mediated transcription. Furthermore, the high Fam124B expression in the 
developing mouse brain and in neuronal tissues at embryonic day E12.5 might indicate a role 
of FAM124B together with CHD8 in neurodevelopmental and autism spectrum disorders.  
In summary, we identified FAM124B, a nuclear protein, as a binding partner of a part of 
CHD7 and CHD8. We conclude that FAM124B is an associated factor of a CHD7 and CHD8 
containing complex. Fam124B is widely expressed at mouse developmental stage E12.5 with 
an overlapping correlation to Chd7 expression and high expression in the developing mouse 
brain. Therefore, we assume a role for FAM124B in the pathogenesis of CHARGE syndrome 
and NDD/ASD. The results of our interaction studies, the subcellular localization, and 
expression profile of FAM124B provide valuable information and represent a starting point for 
further functional investigations on FAM124B and its possible role in CHARGE syndrome and 
NDD/ASD.  
 
MATERIALS AND METHODS 
Ethics statement/mouse strains 
The animal studies are approved by the Institutional Animal Care and Use Committee of the 
University of Göttingen. All mouse studies were performed on CD1 wildtype mice. 
 
Stable isotope labeling by amino acids in cell culture (SILAC) and mass spectrometry (MS)  
Two HeLa cell populations were grown in SILAC DMEM culture media (10% dialyzed FBS 
and 1% penstrep) (PAA Laboratories GmbH, Pasching, Austria; Thermo Fisher Scientific, 
Waltham, MA). The “light” SILAC medium was supplemented with unlabeled L-lysine and L-
arginine, while the “heavy” SILAC medium was supplemented with arginine and lysine 
containing heavy isotopes of carbon and nitrogen (
13
C6-lysine and 
13
C6
15
N4-arginine). Upon 
metabolic labeling of the cells this lead to a mass shift of +6 and +10 Da per incorporated 
arginine and lysine, respectively. After at least 5 cell passages, co-transfection with the 
previously described plasmids CHD7-CR1-3-pCMV-HA and CHD8-pCMV-cmyc [11] into 
either L- or H-labeled HeLa cells was performed. Non transfected L- or H-labeled cells were 
used as negative control. After transient co-transfection, the cells were incubated at 37°C for 
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24 hours, then washed with DPBS (PAN BIOTECH GmbH, Aidenbach, Germany) and 
trypsinized (Invitrogen, Carlsbad, CA, USA). To isolate the same amount of protein from both 
cell cultures, cell populations were accurately counted under microscope using counting 
chambers (Neubauer haemocytometer) (approximately 1 - 1,2 x 107 cells were used) before 
cell lysis, which was performed as described by Oellerich et al. (2011) [24]. Protein lysates 
were incubated with 4 µg of monoclonal anti-Ha antibody (Roche Diagnostik GmbH, 
Mannheim, Germany) at 4°C overnight. Proteins coupled with the antibody were incubated at 
4°C with 100 µl of protein G (Immunoprecipitation Kit, Roche Diagnostik GmbH, Mannheim, 
Germany) for further 2 hours. Centrifugation at 350 rpm for 3 min was carried out to collect 
the agarose beads. To remove unbound proteins, the beads were washed two times in 500 ml 
lysis buffer and one time with 1 ml washing buffer 2 (Immunoprecipitation Kit, Roche 
Diagnostik GmbH, Mannheim, Germany). The beads were resuspended in 50 µl NuPAGE 
LDS Sample buffer (Invitrogen, Carlsbad, CA, USA) supplemented with 0.1 M DTT. After 
denaturation for 10 min at 95°C, the denaturated H- and L-labeled proteins were pooled in 
equimolar amounts and subsequently the samples were separated by size using an 1D-PAGE 
(Invitrogen, Carlsbad, CA, USA) followed by coomassie blue staining. Each gel lane was cut 
into 23 gel slices. Proteins from each slice were in-gel digested with trypsin (Promega, 
Madison, WI) according to the protocol described by Shevchenko et al. (2006) [30]. MS 
measurements were carried out using a nanoflow HPLC (Agilent, Boeblingen, Germany) 
coupled to a nanoelectrospray LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, 
Waltham, MA) as described by Nikolov et al. (2011) [31]. 
RNA isolation and semiquantitative reverse-transcription PCR 
Total RNA was isolated from HeLa cells, MRC-CV1 cells or different mouse tissues using 
Trizol reagent (Invitrogen, Carlsbad, CA, USA). Homogenizing was carried out with Tissue 
lyser LT (Qiagen GmbH, Hilden, Germany). 5 µg of total RNA from each sample was reverse-
transcribed using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). For 
each PCR reaction 0.5 µl undiluted cDNA and 0.2 µl platinum taq polymerase (Invitrogen, 
Carlsbad, CA, USA) was used. Human cDNA isolated from HeLa and MRC-CV1 cells were 
amplified using the following primers: 5’-CCTTCTACACACGCTGTCTTTG-3’as forward 
primer and 5’-GGGGATGAGCTATGCAACCTAAG-3’ as reverse primer. RT-PCR on mouse 
tissues was carried out using the following primer pair: forward primer 5’-
GGTGGCCTTCATCATAATCTTC-3’ and reverse primer 5’-CCAGTCACACTCTTGCT 
TCTGT-3’. The correct sequence was confirmed by sequence analysis. 
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Quantitative RT-PCR 
Realtime PCR reactions were performed using 1μl of 1:10 diluted cDNA from different CD1 
mouse tissues, SYBR green (Invitrogen, Carlsbad, CA, USA) and the gene-specific primers 
forward 5’-CCGTGTGTTCCCATCAGCAG-3’ and reverse 5’- 
CTCCTCCTCCGGCTCCTTG-3’. Relative mRNA expression levels were determined using 
ΔCt values and were normalized to the housekeeping genes Gapdh, Hprt and Sdha. The 
experiment was performed in three biological and 3 technical replicates. 
Co-immunoprecipitation 
For co-immunoprecipitation studies we generated the plasmids FAM124B-1,3-pCMV-HA 
(transcript variant 1, NP_001116251.1), FAM124B-1,2-pCMV-HA (transcript variant 2, 
NP_079061.2), FAM124B-1,3-pCMV-cmyc (transcript variant 1, NP_001116251.1) and 
FAM124B-1,2-pCMV-cmyc (transcript variant 2, NP_079061.2) by cloning the human full-
length sequence of transcript variant 1 and transcript variant 2 in frame to the hemagglutinin 
(HA) epitope tag into the pCMV-HA vector (Clontech, Mountain View, CA, USA) or in 
frame to the N-terminal c-Myc epitope tag into the pCMV-Myc vector (Clontech, Mountain 
View, CA, USA) by using the In fusion advantage kit (Clontech, Mountain View, CA, USA) 
according to the company’s protocol. The correct reading frame and sequence was confirmed 
by sequence analysis. 
Hela cells were cultured in 50 ml flask (Sarstedt, Newton, NC, USA) and were cotransfected 
with CHD7-CR1-3-pCMV-HA (amino acids 1593 - 2178, NP_060250.2) and either 
FAM124B-1,3-pCMV-cmyc or FAM124B-1,2-pCMV-cmyc. Additionally, we co-transfected 
HeLa cells with CHD8-pCMV-cmyc (amino acids 1789 - 2302, NP_065971.2) and either 
FAM124B-1,3-pCMV-HA or FAM124B-1,2-pCMV-HA. After 24h of incubation at 37 °C, co-
immunoprecipitations were carried out as previously described [11]. For immunoblotting we 
used the following antibodies: anti-c-Myc (abcam, ab9106) at a dilution of 1:2000, anti-HA 
(Roche Diagnostik GmbH, Mannheim, Germany) at a dilution of 1:1000, goat anti-CHD7 
(abcam, ab 65097) at a dilution of 1:2000, rabbit anti-CHD8 (abcam, ab84527) at a dilution of 
1:2000. The following antibodies were used for detection: goat anti-rabbit IgG peroxidase 
secondary antibody (Sigma-aldrich, St.Louis, MO, USA) for anti-c-Myc and anti-CHD8, goat 
anti-Rat secondary antibody conjugated with horseradish peroxidase (Thermo Scientific, 
Rockford, IL, USA) for anti-HA, donkey anti-goat IgG peroxidase secondary antibody (Santa-
Cruz Biotechnologies, California, USA) for anti-CHD7. 
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Yeast two hybrid 
For yeast two hybrid studies we generated the constructs FAM124B-1,3-pGBKT7 (transcript 
variant 1, NP_001116251.1), FAM124B-1,2-pGBKT7 (transcript variant 2, NP_079061.2), 
FAM124B-1,3-pGADT7 (transcript variant 1, NP_001116251.1) and FAM124B-1,2-pGADT7 
(transcript variant 2, NP_079061.2). The human full-length sequence of transcript variant 1 
and transcript variant 2 were subcloned in frame to the ATG of the pGBKT7 or pGADT7 
vector (Clontech, Mountain View, CA) by using the In fusion advantage kit (Clontech, 
Mountain View, CA). All constructs were transformed into Y2HGold strain cells (Clontech, 
Mountain View, CA) and tested for toxicity and autoactivation of the bait or prey reporter 
genes. No toxicity for the yeast cells could be observed, but the FAM124B-1,3-pGBKT7 and 
FAM124B-1,2-pGBKT7 showed autoactivation. Therefore, the further experiments were 
performed with the FAM124B-1,3-pGADT7 and FAM124B-1,2-pGADT7 constructs. These 
both plasmids were co-transformed into Y2HGold strain cells together with either the CHD7-
CR1-3-pGBKT7 (amino acids 1591-2181, NP_060250.2) or the CHD8-pGBKT7 (amino acids 
1789–2302, NP_065971.2) plasmids. The direct Yeast two hybrid was performed according to 
the manufactures’ protocol. 
Cryosections 
Adult brains from CD1 mice were isolated and fixed overnight in 4% paraformaldehyde (PFA) 
solution prepared in sterile PBS with DEPC water at 4°C with gentle shaking. On the next day, 
the tissues were washed 3 times with sterile PBS/DEPC at 4°C and incubated in 
autoclaved/sterile 30% Sucrose at 4°C with gentle shaking till the tissues sank down. Then the 
brains were incubated for 30 minutes to 1 hour at 4°C in a 1:1 mixture containing 30% sucrose 
and Jung tissue freezing medium (Leica Microsystems, Nussloch, Germany), following an 
incubation in tissue freezing medium at 4°C for 30 minutes and embedded on dry ice in tissue 
freezing medium. The frozen block was kept till usage at -80°C and cut by cryo-microtome 
(Leica Instrument, Nussloch, Germany) with 20 µm thickness and sticked on Menzel 
Superfrost microscope slides (Thermo Scientific, Rockford, IL, USA).  
In situ hybridization 
In situ hybridization was performed on cryosections of adult brain from CD1 mice. The 
following primer pairs were used to amplify by RT-PCR the whole coding region of Fam124B: 
forward 5’- GCCATGGATGAGATACAGGAA-3’ and reverse 5’- 
CATGAATGGGGCTGACTCTTA-3’. The PCR product was subcloned into pGEMT easy 
vector (Promega, Madison, WI) and transformed into E.coli. Positive plasmids were isolated 
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and sequenced. For probe amplification from a correct plasmid the following primers were 
used for the Sp6 transcript: pGEM-T-Sp6-F (ACGTCGCATGCTCCCG) and pGEM-T-R2 
(CCAGGCTTTACACTTTATGCTTCC) and for the T7 transcript: PCR-T7 
(CTGCGCAACTGTTGGG) and pGEM-T-R1 (AGGCGGCCGCGAATTCAC). The PCR 
products were gelextracted and DIG-labelled RNA probes were synthesized using the DIG 
RNA Labeling Kit (SP6/T7) (Roche Diagnostik GmbH, Mannheim, Germany) according to the 
manufacturer’s protocol. Synthesized probes were ethanol precipitated and resuspended in 100 
µl of DEPC water/formamide 1:1 mixture and kept till usage at -20°C. Non-radioactive in situ 
hybridization have been done according to Moorman et al. (2001) The results have been 
observed using a BX60 microscope (Olympus, Hamburg, Germany) and images were 
processed by the analysis program (CellSens Dimension, Olympus). 
Immunohistochemistry on cells 
HeLa and MRC-CV1 cells were transfected with the FAM124B-1,3-pCMV-HA construct. Cell 
culture, staining procedure and fluorescence imaging was carried out as described previously 
[11]. As a blocking solution 10% sheep serum diluted in DPBS with 0.1% Tween 20 (TPBS) 
was used. Rabbit anti-FAM124B antibody (Proteintech Group, Chicago, IL) was diluted at 1: 
50. As secondary antibody anti-rabbit IgG conjugated with Cy3 (Sigma-Aldrich, St.Louis, 
MO, USA) antibody was used at a dilution of 1:400. 
Immunohistochemistry on paraffin embedded tissues 
Adult wild type CD1 mouse tissues and E12.5 embryos were paraffin embedded according to 
standard procedures. From the paraffin embedded tissues 7µm sections were made and 
incubated overnight at 45 °C. After a three time Xylene incubation (10, 5, 5 minutes) a series 
of ethanol incubation (100%, 95%, 90%, 80%, 70%, 50%) and a washing step with DPBS for 2 
minutes followed. Slides were cooked with antigen retrieval buffer (citric acid 0.1M; EDTA 
0.01%, pH 6.2) in a steam cooker for 10 minutes and allowed retrieval buffer to cool down on 
ice for at least 10 minutes. Endogenous peroxidase activity was blocked using 6% H2O2 
solution in water for 15 minutes. The solution was tapped off from the slides and blocked with 
horse serum (Vectastain Universal Quick kit, Vector Laboratories, Burlingame, CA) for 30 
minutes in a humidity chamber at room temperature. Rabbit anti-FAM124B (Protein Tech), 
rabbit anti-CHD7 (abcam, ab31824) and rabbit anti-CHD8 (abcam, ab84527) antibodies were 
diluted at 1:50, 1:50 and 1:100, respectively. The primary antibodies were incubated at 4°C 
overnight. After washing with TPBS for 5 minutes, a Pan specific secondary antibody 
(Vectastain Universal Quick kit, Vector Laboratories, Burlingame, CA) was applied for 
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maximum 10 minutes and washed again with TPBS for 5 minutes. Streptavidin peroxidase 
(Vectastain Universal Quick kit, Vector Laboratories, Burlingame, CA) was applied on the 
slides for 5 minutes. Slides were then transferred to TPBS washing buffer for minimum 5 
minutes. The staining was developed with DAB substrate (Roche Diagnostik GmbH, 
Mannheim, Germany) for around 2 minutes. The slides were rinsed for minimum 5 minutes 
under tap water and counterstain could be done in mayor’s hematoxylin for 20-40 seconds and 
washed with tap water 3-4 times. Mounting of slides were done with Aqua polymount 
(Polysciences Inc., Warrington, PA). Imaging was performed and processed using a BX60 
microscope (Olympus, Hamburg, Germany) and the analySIS program Cell-Sens Dimension.  
SUPPORTING INFORMATION 
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FIGURES 
Figure 1: Schematic overview of the SILAC 
approach. 
“Heavy”-labeled cells were co-transfected with the 
plasmids CHD7-CR1-3-pCMV-HA (containing amino 
acids 1593 - 2178, NP_060250.2, in fusion with an 
HA-tag) and CHD8-pCMV-cmyc (spanning amino 
acids 1789 – 2302, NP_065971.2, in fusion with an 
cmyc-tag). The CHD7 part was purified by anti-HA 
immunoprecipitation. As a negative control the same 
immunoprecipitation was performed in lysates of non-
transfected “Light”-labeled HeLa cells. Purified 
proteins from both cell cultures were pooled in 
equimolar amounts and in-gel digested, followed by 
liquid-chromatography (LC)-coupled tandem mass 
spectrometry.  
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Figure 2: Co-immunoprecipitation of FAM124B with a part of CHD7 and CHD8. 
HeLa cells were co-transfected with either the CHD7-CR1-3-pCMV-HA (amino acids 1593 - 2178, 
NP_060250.2) plasmid and FAM124B-1,3-pCMV-cmyc/FAM124B-1,3-pCMV-HA (transcript variant 1, 
NP_001116251.1) or with CHD8-pCMV-cmyc (amino acids 1789 - 2302, NP_065971.2) and FAM124B-1,3-
pCMV-HA (transcript variant 1, NP_001116251.1). 
(A) Using the anti-CHD8 (abcam, ab84527) or the anti-CHD7 (abcam, ab31824) antibody for precipitation, we 
detected with the anti-HA antibody (Roche) an approximately 51 kDa band corresponding to the estimated size 
of FAM124B transcript variant 1. Lane 1:  co-transfected Co-IP, lane 2: untransfected HeLa cells as negative 
control. (B) Reciprocal immunoprecipitation with anti-cmyc antibody (precipitating FAM124B transcript variant 
1), and detection with the anti-CHD7 antibody lead to a specific band  ~ 70 kDa, the estimated size for the CHD7 
part fused to the HA-tag. Lane 1:  co-transfected Co-IP, lane 2: untransfected HeLa cells as negative control. (C) 
Reciprocal experiment with anti-HA antibody (precipitating FAM124B transcript variant 1)  and detection with 
the anti-CHD8 antibody detected a specific band ~ 68 kDa, the estimated size for the CHD8 part fused to the 
cmyc-tag. Lane 1: co-transfected Co-IP, lane 2: untransfected HeLa cells as negative control. (D, E, F) The same 
experimental procedure was performed for FAM124B transcript variant 2, demonstrating a specific interaction of 
FAM124B transcript variant 2 with the CHD7 and CHD8 part as well. Lane 1: co-transfected Co-IP, lane 2: 
untransfected HeLa cells as negative control. 
 
Figure 3: Yeast two hybrid assay.  
(A) Direct yeast two hybrid experiment with the 
constructs FAM124B-1,3-pGADT7 (full lengths 
transcript variant 1) and CHD7-CR1-3-pGBKT7 
(amino acids 1591-2181, NP_060250.2) 
demonstrating no direct interaction between 
FAM124B transcript variant 1 and the CHD7 part, 
while (B) direct yeast two hybrid experiment with the 
constructs FAM124B-1,3-pGADT7 (full lengths 
transcript variant 1) and CHD8-pGBKT7 (amino 
acids 1789–2302, NP_065971.2) shows a direct 
interaction. The same experiments were performed 
for FAM124B transcript variant 2. (C) Direct yeast 
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two hybrid experiment with the constructs FAM124B-1,2-pGADT7 (full lengths transcript variant 2) and CHD7-
CR1-3-pGBKT7 (amino acids 1591-2181, NP_060250.2). (D) Direct yeast two hybrid experiment with the 
constructs FAM124B-1,2-pGADT7 (full lengths transcript variant 2) and CHD8-pGBKT7 (amino acids 1789–
2302, NP_065971.2). FAM124B transcript variant 2 interacts directly with the CHD8 part, while no direct 
interaction with the CHD7 part could be observed. 
 
 
 
Figure 4: Subcellular localization of 
FAM124B.  
(A) Immunofluorescence staining using a 
rabbit anti-Fam124B antibody 
(ProteinTech) on untransfected HeLa cells 
demonstrating a mainly nuclear localization 
of endogenous FAM124B. 
(B) Immunofluorescence staining using the 
rabbit anti-Fam124B antibody and the anti-
HA antibody on HeLa cells transiently 
transfected with the plasmid FAM124B-
1,3-pCMV-HA (FAM124B transcript 
variant 1 fused to an hemagglutinin tag) 
confirmed the mainly nuclear distribution of 
FAM124B and demonstrated the specifity of the FAM124B antibody. 
(C) Immunofluorescence staining using the rabbit anti-Fam124B antibody and the anti-cmyc antibody on HeLa 
cells transiently transfected with the plasmid FAM124B-1,3-pCMV-cmy (FAM124B transcript variant 1 fused to 
an cmyc tag) confirmed the further results. Scale bar = 10 µm. 
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Figure 5: Expression pattern of murine Fam124B 
(A) Expression pattern of murine Fam124B by semiquantitative reverse transcription polymerase chain reaction 
(RT-PCR) on wild type CD1 mouse tissues and E9.5 and E12.5 embryos demonstrating expression in various 
tissues and during development. 
(B) Immunohistochemistry (IHC) performed in adult mouse tissues slightly counterstained with haemytoxylin 
(blue) confirmed the semiquantitative RT-PCR results with high expression (brown) in lung, heart, kidney, 
moderate expression in brain and testis, and very low expression in liver. Scale bar = 20 µm. 
 
 
Figure 6: Fam124B expression in the mouse central nervous system. 
(A) Overview of horizontal paraffin embedded brain sections (B, C, D). (G) Overview of sagittal brain 
cryosections (E,F). (B) Cortex, (C) Thalamic nuclei, (D) Hippocampus, (E) Caudate Putamen, (F) Cerebellum.  
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Ctx = Cortex, CC = Corpus Callosum, Hipp = Hippocampus, CA1-3 = Cornu Ammonis areas, DG = dentate 
gyrus, CP = Caudate Putamen, adt = anterior dorsal thalamic nucleus, dg = granual layer of dentate gyrus, lv = 
left ventricle, F = fornix, mdt = mediodorsal thalamic nucleus, IIIv = third ventricle with choroid plexus, vpl = 
ventral posterior thalamic nucleus, lateral part, SM = stratum moleculare, SP = stratum purkinjense, SG = 
stratum granulosum, II = stratum granulosum externum.  Scale bar = 100 µm. 
 
 
Figure 7: In situ hybridization (ISH) of Fam124B on mouse brain cryosections in comparison with 
immunostaining (IHC). (A) Cortex, (B) Hippocampus: An overlapping expression pattern could be 
demonstrated confirming the specificity of the FAM124B antibody. DG = dentate gyrus. Scale bar =100µm. 
 
 
Figure 8: Fam124B expression at murine embryonic stage E12.5 
Fam124B expression (brown) was found in a variety of embryonic tissues. Expression could be observed in 
several brain areas, spinal cord, dorsal root ganglia, developing cochlea and surrounding tissues, lung, heart, and 
kidney. Low expression was found in the developing liver and no expression (blue) in blood cells.  
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(A) Overview of Fam124B immunostaining on sagittal section of an E12.5 wildtype embryo slightly 
counterstained with haemytoxylin, scale bar = 200 µm. Higher magnification of (B) dorsal root ganglia, scale bar 
= 100 µm (C) nasal region, scale bar = 100 µm (D) the developing heart, scale bar = 100 µm (E) developing 
liver, scale bar = 50 µm (F) spinal cord (sc), scale bar = 50 µm  (G) developing lung with segmental bronchus 
(sb), scale bar = 100 µm (H) cochlea, and surrounding tissue, scale bar = 100 µm. 
LV = lateral ventricle, ch.p = choroid plexus differentiating from fourth ventricle, co = cochlea, cd = cochlear 
duct, ne = nasal epithelium, V gan = left trigeminal (V) ganglion, drg = dorsal root ganglion, VIII gan = 
Vestibulocochlear (VIII) ganglion, at = left atrium of heart, vt = left heart ventricle, ec = endothelial cells, car = 
cartilage primordium of body of vertebra, ccp = cartilage condensation being primordium of vertebral body.  
 
 
Figure 9: Fam124B expression in the developing brain at murine embryonic stage E12.5 
(A) Overview of Fam124B immunostaining of the brain slightly counterstained with haemytoxylin. (B) Higher 
magnification of the trigeminal ganglion, (C) aqueduct of sylvius with choroid plexus = AQ (D) Higher 
magnification of the medulla (me) with spinal tract of trigeminal nerve (Vsp), nV = trigeminal nucleus, MLF= 
medial longitudinal fasciculus  (E) Higher magnification of the eye, nr = neural retina, lf = lens fibers, vb = 
vitreous body. Scale bar = 50 µm. 
 
 
 
 
 
 
 
 
 
Results 
 
50 
 
 
Discussion 
51 
 
4. Discussion 
Mutations in the chromodomain helicase DNA binding protein 7 gene (CHD7) are the 
underlying cause for CHARGE syndrome, an autosomal dominant inherited heterogeneous 
multiple malformation syndrome (Vissers et al. 2004).  In 10-20% of patients with typical 
signs of CHARGE syndrome and in 40-50% of patients with an atypical presentation no 
mutation could be found and therefore the molecular cause is unknown. The characterization of 
CHD7 interacting partners can help to understand the pathogenesis of the disease. In our 
working group a part of CHD8, another member of the CHD family of proteins, was identified 
by yeast two hybrid library screen as a putative interaction partner of CHD7. The interaction 
was confirmed by bimolecular fluorescence assay (BiFC), direct Yeast two Hybrid and Co-IP 
experiments. Furthermore, we investigated the CHD7-CHD8 interaction in the presence of 4 
CHD7 missense mutations. Indeed, three out of 4 mutations lead to a loss of interaction by 
direct interaction studies, while the interaction still remained in Co-IP studies. Because of these 
results we suggest that CHD7 and CHD8 interact directly (shown by the Y2H experiments) 
and indirectly via additional linker proteins (in Co-IP results). Therefore we searched for 
additional CHD7 and CHD8 associated proteins by using the method of SILAC in combination 
with mass spectrometry.  As a novel interacting partner of a part of CHD7 and a part of CHD8 
we identified the unknown protein FAM124B. We further characterized the expression profile 
and the subcellular localization of FAM124B. Moreover, our results let us suggest that 
FAM124B might be very important for embryonic development and could play a role in the 
pathogenesis of CHARGE syndrome and autism and neurodevelopmental disorders. 
 
4.1 Known CHD7 complexes and function 
Since the discovery that CHD7 mutations lead to CHARGE syndrome, its functions have 
been studied to a greater extent. To date, CHD7 is known to be involved in several cell and 
tissue specific complexes (Takada et al. 2007, Bajpai et al. 2010, Schnetz et al. 2009, 2010). In 
human multipotent neural crest like cells, CHD7 regulates neural crest and placode formation 
by binding to components of the BAF/PBAF complex (Bajpai et al. 2010, Fig. 4.1A). 
BAF/PBAF complexes are chromatin remodeling complexes, which are involved in 
developmental transitions. The composition of the complex is tissue and developmental stage 
dependent (Ho & Crabtree 2010).  
With an approach of chromatin immunoprecipitation and microarray-based sequence 
analysis (ChIP-chip) in human colorectal carcinoma cells, human neuroblastoma cells, and 
mouse ES cells before and after differentiation into neural precursor cells, CHD7 has been 
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demonstrated to have tissue and cell type specific temporal functions via localizing to 
methylated histone H3 lysine 4 (H3K4) in enhancer regions of various genes (Schnetz et al. 
2009). A further study in mouse embryonic stem (ES) cells indicates that CHD7 colocalizes 
with Oct4, Sox2, Nanog, and p300 and functions by binding to enhancers as a transcriptional 
modulator and fine-tuning the expression levels of ES cell–specific genes in either a positive or 
negative way (Schnetz et al. 2010, Fig. 4.1B). In addition, CHD7 forms a complex with NLK, 
SETDB1 and PPAR-γ and binds to methylated lysine 4 and lysine 9 residues on histone H3 at 
PPAR-γ target promoters in mesenchymal stem cells. Therefore it is suggested that CHD7 is 
involved in the regulation of cell fate specification (Takada et al. 2007, Fig. 4.1C).  
Furthermore, in Drosophila, Kismet, a homolog of the human CHD7 protein, has been 
proven to be crucial for proper axon pruning and development of fly’s central nervous system 
(Melicharek et al. 2010). Another functional study could demonstrate that Kismet promotes 
early transcriptional elongation through RNA polymerase II by recruiting the histone 
methyltransferases ASH1 and TRX to chromatin (Srinivasan et al. 2008).  
CHD7 is localized in the nucleolus and the nucleoplasm (Zentner et al. 2010, Kita et al. 
2012). Interestingly, recently it has been shown that CHD7 codes for two transcripts. The 
shorter transcript is generated by alternative splicing of exon 6 and contains only one 
chromodomain. This transcript variant was shown to localize in the nucleolus (Kita et al. 
2012). CHD7 regulates positively rRNA biosynthesis and is associated with rDNA (Zentner et 
al. 2010). Indeed, it has been shown that both CHD7 transcripts regulate 45S precursor rRNA 
production (Zentner et al. 2010, Kita et al. 2012). Moreover overexpression studies showed 
that the long CHD7 transcript (CHD7L) supports Sox2-mediated transcriptional regulation 
whereas the short CHD7 transcript (CHD7S) suppresses it (Kita et al. 2012). Treacher Collins 
syndrome (TCS) is a multiple congenital anomaly caused by mutations in the TCOF1 gene, 
encoding the protein treacle (Valdez et al. 2004, Dixon et al. 2007). TCS and CHARGE 
syndrome are distinct diseases, but share some common features such as eye and ear defects. 
Like CHD7, treacle is associated on rDNA and act as a positive regulator of rRNA synthesis. 
Indeed, Zentner et al. (2010) could show that CHD7 is needed for treacle (TCOF1) to associate 
with rDNA (Fig. 4.1D). These findings imply a functional link between CHARGE syndrome 
and Treacher Collins syndrome. 
These reports show crucial roles for CHD7 in the transcriptional regulation of target 
genes, its effects on developmental stages and various tissue specific processes and the 
pathogenetic connection between CHARGE syndrome and other malformation syndromes like 
Treacher Collins syndrome.  
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Figure 4.1. Models for CHD7 complexes. A: Human neural crest-like cells, BAF/PBAF complex (Bajpai et al. 
2010), B: A complex in mouse embryonic stem cells (Schnetz et al. 2010), C: A complex in mouse bonemarrow 
mesenchymal progenitor cells (Takada et al. 2007), D: CHD7 and Treacle association on rDNA (Zentner et al. 
2010). 
 
4.2 Known CHD8 complexes and function 
Chromodomain helicase DNA binding protein 8 (CHD8) is a chromatin remodeling 
enzyme that belongs to the CHD subgroup III. Typical additional domains of this subgroup are 
three conserved regions (CR1-3), a SANT and two BRK domains. CHD proteins utilize ATP 
hydrolysis to modify chromatin structure and to regulate transcriptional processes (Marfella & 
Imbalzano 2007).  CHD8 was first described in Xenopus by Sakamoto et al. (2000). They 
named the protein Duplin (for axis duplication inhibitor). It was shown that Duplin is a nuclear 
protein that directly binds to β-catenin and inhibits Wnt/β-catenin signaling (Sakamoto et al. 
2000). The second chromodomain is responsible for the β-catenin interaction. In addition, they 
could show that Duplin regulates β-catenin- T-cell factor (Tcf)-dependent downstream genes 
(Chung et al. 1997, Kobayashi et al. 2002). However, Duplin is an N-terminal fragment of 
Chd8 which lacks the catalytic Snf2 helicase domain and all further domains. Later, full length 
of CHD8 has been shown to bind also directly to β-catenin (Thompson et al. 2008). 
Nishiyama et al. (2004) created Duplin knock-out mice. Duplin mutant homozygous 
embryos show growth retardation accompanied by massive apoptosis leading to death at E7.5. 
Later they demonstrated CHD8 binds to both p53 and histone H1 proteins. The p53–CHD8–
histone H1 complex is required for suppression of p53 target genes transcription, and therefore 
Mouse embryonic stem cells Mouse BM mesenchymal 
progenitor cells 
A B C 
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prevents apoptosis induced by genotoxicity (Nishiyama et al. 2009, Fig. 4.2A). Interestingly, 
the Wnt signaling pathway is regulated by CHD8 in a similar way. CHD8 promotes the β-
catenin–CHD8–histone H1 trimeric complex on chromatin (Nishiyama et al. 2012, Fig. 4.2B).  
CHD8 is shown to be involved in various protein complexes depending on the cell type 
and developmental stage. Mouse Chd8 has been shown to play a role in Ctcf-dependent 
insulator function by binding directly Ctcf (11-zinc finger protein or CCCTC-binding factor) 
(Ishihara et al. 2006). Furthermore, various experiments on smooth muscle cells (SMCs) could 
demonstrate that complexes including CHD8, Serum Response Factor (SRF) and CCTF play 
an essential role in differentiation and maintenance/survival of SMCs (Rodenberg et al. 2010, 
Fig. 4.2C). 
Additionally, CHD8 was copurified with a large protein complex including Wdr5, Ash2L, 
and RbBP5 (WAR), which are known members of the Mixed Lineage Leukemia (MLL) 
histone modifying complex (Dou et al. 2005, Thompson et al. 2008, Yates et al. 2010, Fig. 
4.2D). MLL1 or 2, the trithorax orthologs in Drosophila, built together with RbBP5-WDR5 
and ASH2L a complex which acts as a methyltransferase. This complex composition regulates 
the HOXA2 gene transcription in a positive manner (Hess 2004, Wysocka et al. 2005). In 
contrary, it has been demonstrated through CHD8 shRNA downregulation in pluripotent 
human testicular embryonal carcinoma cell lines that CHD8 with the WAR complex members 
WDR5, ASH2L and RbBP5 negatively regulates HOXA2 expression (Yates et al. 2010).   
CHD8 interacts with the human Staf protein for efficient U6 gene transcription in vivo and  
it has been demonstrated by Chip analysis that CHD8 binds to both Pol II and Pol III snRNA 
promoters (Yuan et al. 2007).  Moreover, CHD8 binds specifically to histone H3 di-methylated 
at lysine 4 with its chromodomains (Rodríguez-Paredes et al. 2009). CHD8 also binds the 
elongating form of RNA polymerase II to control the expression of cyclin E2 and thymidylate 
synthetase (TYMS) (Rodríguez-Paredes et al. 2009). 
In addition, CHD8 is associated directly with the androgen receptor (AR) which could 
demonstrate a role for CHD8 in AR-mediated regulation of target genes (Menon et al. 2010).  
Collectively, CHD8 has various interaction partners depending on the cell type. Depending on 
the complex partners CHD8 functions in different processes like repressing apoptosis, 
differentiation and survival of SMCs, transcriptional repression and regulation of specific 
target genes. 
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Figure 4.2. Models for CHD8 complexes. A: p53–CHD8–histone H1 complex regulates apoptosis during 
embryogenesis (Nishiyama et al. 2009), B: CHD8 interacts with β-catenin and subsequently recruits histone H1, 
resulting in chromatin compaction and transcriptional silencing of Wnt target genes (adapted and modified from 
Nishiyama et al. 2012), C: CHD8, SRF and CCTF complex is important for differentiation and survival of smooth 
muscle cells (Rodenberg et al. 2010), D: The human WAR (WDR5, RbBp5, ASH2L) complex repress HOXA2 
gene expression when CHD8 is included (Thompson et al. 2008). 
 
4.3 CHD8 builds together with CHD7 a complex 
In our working group we searched for CHD7 interaction partners by performing yeast two 
hybrid library screen of a human fetal brain library. CHD8 was identified as a potential CHD7 
interaction partner. The interaction was confirmed by direct yeast two hybrid and in HeLa cells 
by Co-IP and BiFC-assay (bimolecular fluorescence complementation assay). Interestingly, 
when we narrow down the interacting area of CHD8, a region of unknown functions without 
predicted domains was identified. The predicted sizes of the CHD7 and CHD8 proteins are 334 
kDa and 290 kDa, respectively.  Because of such a huge size of the endogenous CHD7 and 
CHD8 proteins, western blot detection needs to be done by a harsh nuclear isolation protocol 
as well as wet blotting technique. CHD8 is expressed relatively strong in HeLa cells 
(Nishiyama et al. 2009, 2012), whereas endogenous CHD7 expression is very low. Therefore, 
we were not able to perform Co-IP experiments with endogenous CHD7 in HeLa cells (data 
not shown). To demonstrate, the endogenous CHD7-CHD8 interaction we used the new 
method of Proximity Ligation Assay (PLA, Olink) (Fig. 4.3). In this method, two target 
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proteins can be detected with specific antibodies produced in two different species. Specific 
oligonucleotide labeled secondary antibodies (PLA probes) generates fluorescence spots only 
when the two PLA probes have bound in close proximity. In our case, the PLA probes produce 
red fluorescence spots. 
 
       
          
Figure 4.3. CHD7 and CHD8 endogenous interaction in HeLa cells shown by the Duolink PLA method.  
Cell nuclei were counterstained with DAPI and cytoskeleton was stained by Phalloidin/FITC. Interacting areas are 
visualized as red fluorescence spots. A: CHD7 and CHD8 interaction can be seen in the nucleus. B: Technical 
negative control for the CHD7 and CHD8 antibodies. The primary CHD7 and CHD8 antibodies are used 
separately with 2 PLA probes. There are very few red dots in negative control which indicates antibodies do bind 
specifically (done by Yvonne Schulz 2011). 
Moreover, in mammals CHD3 and CHD4, two other members of the CHD family, build 
together a core component of the NuRD complex (Xue et al. 1998, Hall & Georgel 2007).  In 
lower organisms like Drosophila, not all orthologs of the known human CHD genes are 
existing. For instance, Kismet is the only ortholog of all human CHD subgroup III members in 
Drosophila. Kismet mutant Drosophila larvae showed more severe influence on some 
transcription factors than CHD7, CHD8 or CHD9 solely did in mammals (Srinivasan et al. 
2005, Rodríguez-Paredes et al. 2009). Because of these observations, it is suggested that other 
CHD subgroup members might have overtaken functions of Kismet. Furthermore, it is 
hypothesized that depletion of one CHD subgroup member leads to a gene-specific, but not a 
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general influence (Rodríguez-Paredes et al. 2009). Deletions of the region 14q11.2 including 
the CHD8 and SUPT16H gene have been found in three patients with facial dysmorphism, 
developmental delay and cognitive impairments (Zahir et al. 2007). The authors concluded that 
haploinsufficiency of either the CHD8 and/or the SUPT16H are the reason for the phenotype 
in the patients (Zahir et al. 2007). Even though these patients’ phenotype is different from 
CHARGE syndrome, we considered that missense mutations in the CHD8 gene disturbing the 
function of its interacting partner CHD7 might lead to CHARGE syndrome. Therefore, we 
analyzed in our working group 25 CHD7 negative CHARGE syndrome patients for missense 
mutations in the CHD8 gene. We did not find a pathogenic CHD8 mutation in our collective 
(Batsukh et al. 2010).  Interestingly, it has been reported recently that some patients with 
autism (ASD) and neurodevelopmental disorders (NDD) have de novo missense or nonsense 
mutations in the CHD8 gene as well as microdeletions (Zahir et al. 2007, Neale et al. 2012, 
O`Roak et al. 2012, Talkowski et al. 2012). Because of these results, it is now clear that CHD8 
mutations are not an underlying cause of CHARGE syndrome, but interestingly about two 
thirds of children with CHARGE syndrome suffer from autism spectrum disorders (Betancur 
2011). Our findings that CHD7 and CHD8 interact with each other might shed some light in 
the understanding of the connection between ASDs/NDDs and CHARGE syndrome. 
 
 4.4 Evaluating the effect of 4 CHD7 missense mutations on the interaction between 
CHD8 and CHD7  
We wanted to check if the CHARGE syndrome causing CHD7 missense mutations have 
an effect on the CHD7-CHD8 interaction (Batsukh et al. 2010). We studied the three known 
CHD7 mutations (p.His2096Arg, p.Val2102Ile and p.Gly2108Arg) (Felix et al. 2006, Lalani et 
al. 2006, Jongmans et al. 2008) as well as a mutation newly identified in our lab 
(p.Trp2091Arg). All four missense mutations are within the CHD7 part involved in the CHD7-
CHD8 interaction (Batsukh et al. 2010). Interestingly, all four missense mutations lead to a 
phenotype in the patients classified as atypical CHARGE syndrome (Felix et al. 2006, Lalani 
et al. 2006, Jongmans et al. 2008, Batsukh et al. 2010). In direct Y2H experiments three 
(p.Trp2091Arg, p.His2096Arg and p.Gly2108Arg) of the four missense mutations disrupt the 
CHD7-CHD8 interaction. Our patient with the missense mutation p.Trp2091Arg has bilateral 
coloboma and microphthalmia of the left eye, microcephaly, unilateral deafness and mental 
retardation (Batsukh et al. 2010). Only one out of five affected members of two families with 
the missense mutation p.Gly2108Arg fulfilled the diagnostic criteria for CHARGE syndrome 
while the others showed a very mild phenotype (Jongmans et al. 2008) 
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In contrast, Co-IP interaction study showed no disruption in CHD7-CHD8 interaction by 
the four missense mutations in the CHD7 part. While the Y2H is a good technique to test direct 
interactions between proteins, the Co-IP is a method which allows purifying the whole 
complex. Because of the Co-IP results, we hypothesize that there must be a linker protein 
which still keeps the mutated CHD7 together with CHD8 in the same complex (Batsukh et al. 
2010). Therefore, we further searched for possible linker proteins that could help us to 
understand the pathomechanism behind CHD7 mutations (see next 4.5). 
 
        
Figure 4.4. Hypothetical Enhancer and Promoter interaction via CHD7 and CHD8 containing 
protein/transcription factors (TF) complex mediated DNA-loop model. Protein and protein interactions 
between various TFs (including CHD7 and CHD8) and RNA pol II activate transcription (Modified from Garrath 
& Grisham Biochemistry, 1999) (Thompson et al. 2008, Schnetz et al. 2010). 
Collectively, from these studies we suggest a hypothetical DNA-loop model which is 
mediated by CHD7 and CHD8 containing protein complexes and leading to an enhancer and 
promoter interaction (Fig. 4.4). Furthermore, it can be postulated that CHD7 and CHD8 can 
build a core component of one big complex, probably present in a cell type and developmental 
stage specific manner. Further characterization of these complexes can help to understand the 
pathogenesis of CHARGE syndrome. 
 
4.5 FAM124B is associated with CHD7 and CHD8 
Our interaction study of CHD7 and CHD8 led us to conclude that both proteins are 
components of a huge complex, with additional proteins acting as linker proteins between 
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CHD7 and CHD8. Therefore, we used the method of SILAC in combination with mass-
spectrometry to further characterize such complex. In particular, we could find FAM124B as a 
potential interaction partner of CHD7 and CHD8 in all three repetitions of the experiment 
(manuscript in submission stage: Batsukh et al. 2012). We could confirm the interaction of 
FAM124B with both CHD7 and CHD8 by Co-IP. However, a direct interaction investigated by 
Yeast two hybrid experiments could only be demonstrated for both FAM124B transcripts with 
a CHD8 part, containing a region of unknown function and one BRK domain (amino acids 
1789–2302). No interaction could be seen between FAM124B and the CHD7 part containing 
the CR1-3/SANT domain region (amino acids 1591-2181). Probably FAM124B interacts with 
CHD7 by binding to another than the tested region or via CHD8 or additional proteins (see 
4.7).  
 
4.6. Subcellular localization and expression profile of Fam124B in comparison of Chd7 
and Chd8 
We further investigated the subcellular localization of FAM124B. We could demonstrate 
that endogenous FAM124B is localized mainly in the nucleoplasm. CHD8 is a nuclear protein 
(Ishihara et al. 2006) whereas CHD7 is shown to be expressed in nucleolus and nucleoplasm 
(Zentner et al. 2010, Kita et al. 2012). Thus, we suggest the interaction between FAM124B, 
CHD8 and CHD7 might be in the nucleoplasm.  
CHD7 expression patterns in all analyzed species (Human, mouse, chicken, zebrafish) are 
congruent with the organs affected in CHARGE syndrome (Bosman et al. 2005, Lalani et al. 
2006, Sanlaville et al. 2006, Aramaki et al. 2007, Patten et al. 2012). Therefore, we analyzed 
the expression of Fam124B in comparison with Chd7 and Chd8 by immunostaining on 
different adult and embryonic mouse tissues (Fig 4.5-7). All the positive stained cells show 
brown color. The expression pattern of Fam124B correlates in the cornu ammonis of the 
hippocampus and in the cortex nicely with the Chd8 expression pattern. Chd7, Chd8 and 
Fam124B are all three highly expressed in the stratum purkinjense of the cerebellum (Fig. 4.5). 
Because it is known that Chd8 and Chd7 are highly expressed during early embryogenesis and 
the expression is decreased in some adult tissues (Nishiyama et al. 2004, 2009, Bosman et al. 
2005) we expanded our studies on E12.5 mouse embryos.  
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Figure 4.5. Immunostaining Fam124B of adult brain shown in comparison with Chd7 and Chd8.  
Counterstained with hematoxylin eosin. A: Cerebellum, SP- stratum purkinjense; B: cortex area, C: Cornu 
ammonis of hippocampus (CA) and dentate gyrus (DG) area. 
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Figure 4.6. Chd7, Chd8 and Fam124B immunostainings on sagittal sections of an E12.5 wildtype embryo. 
Counterstained with hematoxylin eosin. A: Overview of immunostainings on sagittal section of an E12.5 wildtype 
embryo, LV = lateral ventricle, ch.p = choroid plexus differentiating from fourth ventricle, co = cochlea, cd = 
cochlear duct, ne = nasal epithelium, V gan = left trigeminal (V) ganglion, drg = dorsal root ganglion, VIII gan = 
Vestibulocochlear (VIII) ganglion, L = liver,  na-nasal region, ccp = B: the developing heart, at = left atrium of 
heart, vt = left heart ventricle, ec = endothelial cells, C: dorsal root ganglion, car = cartilage primordium of body 
of vertebra, ccp = cartilage condensation being primordium of vertebral body, ln=lumbar nerve, drg=dorsal root 
ganglion.  
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Figure 4.7.  Chd7, Chd8 and Fam124B immunostaining on coronal sections of the E12.5 mouse embryo.  
Counterstained with hematoxylin eosin. A: Overview of the immunostaining of E12.5 embryo, B: Higher 
magnification of the embryonic eye, nr = neural retina, lf = lens fibers, vb = vitreous body, C: Higher 
magnification of the trigeminal ganglion. 
 
In sagittal and coronal sections of E12.5 embryos, the developing heart, the dorsal root 
ganglia, and the developing eyes were strongly stained by the Chd7, Chd8 and Fam124B 
antibodies (Fig. 4.6, 4.7). Our Chd7 results fit with the results of Chd7 expression study 
performed on E12.5 mouse tissues, which demonstrated high expression in the developing 
brain (ventricles, hypothalamus, olfactory epithelium, olfactory tissues, pituitary, olfactory 
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sensory neurons, vestibulocochlear ganglion, dorsal root ganglia, developing lung and heart) 
(Bosman et al. 2005). Lowest expression could be observed in the developing liver (Fig. 4.6).  
Fam124B expression at E12.5 was found in several brain areas, spinal cord, dorsal root 
ganglia, cochlea and surrounding tissues, lung, heart, and kidney. Therefore, Fam124B 
expression pattern correlates in many embryonic tissues with the Chd7 expression pattern.  
We demonstrated that FAM124B is a nuclear protein which possibly builds together with 
CHD7 and CHD8 a complex. Fam124B is highly expressed at mouse developmental stage 
E12.5 with an overlapping correlation to Chd7 expression and a correlation to Chd8 expression 
especially in the developing mouse brain. Therefore, we assume a role for FAM124B in the 
pathogenesis of CHARGE syndrome and ASD/NDD.  
 
4.7 Structure and Function of FAM124B 
FAM124B is localized on chromosome 2q36.2. It has two transcripts in human and 
chimpanzee and only one in mouse and other species which is homologous to the longer 
human transcript. FAM124B is an evolutionary highly conserved protein which could have an 
important role in the cell (see 4.6). By bioinformatic prediction programs, we could not find 
any functional domain in FAM124B. Interestingly, alignment of the amino acid sequence of 
FAM124B from human to zebrafish revealed an area containing human amino acids 109-255 
which show 100% homology between the species (Fig. 4.8). These data imply us that this 
region could contain an important hitherto unknown domain motif or this region is of 
functional relevance. Further investigations to clarify this aspect are needed. 
In our study we could show that in vivo and in vitro FAM124B is localized in the 
nucleoplasm (manuscript in submission Batsukh et al. 2012). No previous characterization and 
functional studies on FAM124B gene have been performed. In order to identify additional 
proteins which interact with FAM124B, we overexpressed the FAM124B transcript variant 1 
(longer transcript variant, NP_001116251.1 3) in HeLa cells and performed a pull down with 
the anti-Ha (Roche) antibody followed by SDS-PAGE electrophoresis separation and mass-
spectrometry analysis (data not shown). Interestingly, two times out of three repetitions of the 
experiment we detected treacle, the protein mutated in Treacher Collins syndrome. It was 
shown that treacle and CHD7 bind to rDNA. Furthermore, it was demonstrated that the 
absence of CHD7 impaired the ability of treacle to bind rDNA (Zentner et al. 2010). Therefore, 
the authors suggest a connection between CHD7 and treacle and moreover they hypothesized a 
functional link between CHARGE and Treacher Collins syndrome (see 4.1). From our data we 
suggested that possibly treacle builds a complex together with CHD7, CHD8 and FAM124B. 
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Figure 4.8. A homologous part of FAM124B protein alignment from Human to Zebrafish by Constraint-
based Multiple alignment tool (COBALT, http://www.ncbi.nlm.nih.gov/tools/cobalt/). 145 to 224 amino acid 
sequence of Human FAM124B shows 100% homology with all the other species.  
 
Additionally, we could identify 3 times KU70, an ATP-dependent helicase II as a 
FAM124B interaction partner. KU70 was shown to interact with p53, a protein which interacts 
with CHD8 (Feki et al. 2005, Nishiyama et al. 2009). Therefore, FAM124B might have like 
CHD7 or CHD8 different functions, is involved in different mechanisms and is part of 
different complexes, maybe in a cell type and developmental stage dependent manner.  
 
4.8 Future endeavors and perspectives  
In the current study we have identified two new components of CHD7 containing 
complexes, CHD8 and FAM124B. 
CHD8 mutations or disruptions are reported to be responsible for ASD/NDDs. Autism 
spectrum disorders are commonly associated with CHARGE syndrome. With the current study 
we provide the first functional link between these two conditions. A further characterization of 
CHD7 and CHD8 containing complexes is necessary to get deeper insights into the 
pathomechanism behind ASD/NDD and CHARGE or other related malformation syndromes. 
Such functional link at the molecular level was described in the literature for CHARGE 
syndrome and Treacher Collins syndrome, a clinically distinct disorder but affecting the same 
organ systems. TCOF1, the gene mutated in Treacher Collins syndrome and CHD7 co-
associate at rDNA (Zentner et al. 2010). Possibly, the characterization of CHD7 and CHD8 
complexes can also explain the overlap in the clinical features between CHARGE and other 
related disorders.  
CHARGE syndrome belongs to the group of “neurocristopathies”. Many of the symptoms 
seen in those syndromes are hypothesized to be the result from abnormalities in the 
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development, migration, or interaction of the cephalic neural crest cells (Siebert et al. 1985). 
Indeed, Bajpai et al. (2010) could demonstrate by CHD7 knockdown studies in Xenopus laevis 
embryos that CHD7 is crucial for neural crest cell (NCC) formation and migration into the 
pharyngeal arches. We could observe the same effect in our group (Fig. 4.9). 
 
                 
 
 
 
 
 
     
 
 
Figure 4.9. Effect of CHD7 knockdown on expression of transcription factor Twist involved in neural crest 
formation. Two cell-stage Xenopus laevis embryos were injected with Control morpholino (CoMO, 20ng) and 
CHD7 morpholino  (CHD7 MO, 10ng and 20ng) asymmetrically into a single blastomere and analyzed by whole 
mount in situ hybridization at neurula stage (st.21 and 26) to visualize expression pattern of Twist, a transcription 
factor that controls early neural crest formation.  A: Xenopus laevis stage 21.  B: stage 26, left (L) and right (R) 
side of the embryos. Red arrows indicate migrating neural crest cells while black arrow shows disrupted neural 
crest migration which CHD7 MO was injected. In CHD7 knockdown part, neural crest formation is severely 
affected which shows no expression of Twist (done by Yvonne Schulz 2012). 
 
 
In the current study we identified the hitherto uncharacterized protein FAM124B as a 
novel component of a CHD7 and CHD8 containing complex. We examined the expression 
profile and subcellular localization but functional studies are still needed. It will be interesting 
to prove if a knockdown of FAM124B in Xenopus laevis embryos will lead to an abnormal 
formation and migration of neural crest cells, as well. Furthermore, it will be of great interest if 
an overexpression of FAM124B in Xenopus laevis embryos with a CHD7 knockdown can 
B 
A 
Co MO, 20ng CHD7 MO, 10ng 
Co MO, 20ng CHD7 MO, 10ng CHD7 MO, 20ng 
L L 
R R 
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rescue the CHD7/CHARGE phenotype and if a knockdown of FAM124B and CHD7 together 
show a more severe synergistic effect. 
Additionally, the creation and characterization of a “loss of function” FAM124B mouse 
model will provide information if a mutated FAM124B lead to CHARGE or a CHARGE 
related syndrome. In our working group, a FAM124B mutation screening of CHD7 negative 
CHARGE patients is already in progress. We believe that such studies can elucidate another 
gene involved in CHARGE syndrome and can explain the multiple defects seen in the patients.  
 
 
 
References 
 
67 
 
5. References  
Adams ME, Hurd EA, Beyer LA, Swiderski DL, Raphael Y, Martin DM. (2007) Defects in 
vestibular sensory epithelia and innervation in mice with loss of Chd7 function: implications 
for human CHARGE syndrome. J Comp Neurol. 504:519–532. 
Airio A, Pukkala E, Isomaki H. (1995) Elevated cancer incidence in patients with 
dermatomyositis: a population based study. J Rheumatol. 22:1300–1303.  
Akhtar A, Zink D, Becker PB. (2000) Chromodomains are protein-RNA interaction modules. 
Nature. 407:405–409. 
Allis CD, Jenuwein T, Reinberg D, Caparros ML (editors). (2007) Epigenetics, Cold Spring 
Harbor Laboratory Press, Cold Spring Harbor, New York. p.240. 
Aramaki M, Udaka T, Kosaki R, Makita Y, Okamoto N, Yoshihashi H, Oki H, Nanao K, 
Moriyama N, Oku S, Hasegawa T, Takahashi T, Fukushima Y, Kawame H, Kosaki K. (2006) 
Phenotypic spectrum of CHARGE syndrome with CHD7 mutations. J Pediatr. 148:410-414. 
Asakura Y, Toyota Y, Muroya K, Kurosawa K, Fujita K, Aida N, Kawame H, Kosaki K, 
Adachi M. (2008) Endocrine and radiological studies in patients with molecularly confirmed 
CHARGE syndrome. J Clin Endocrinol Metab. 93:920–924. 
Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H, Mills 
AA. (2007) CHD5 is a tumor suppressor at human 1p36. Cell. 128(3):459-475.  
Bajpai R, Chen DA, Rada-Iglesias A, Zhang J, Xiong Y, Helms J, Chang CP, Zhao Y, Swigut 
T, Wysocka J. (2010) CHD7 cooperates with PBAF to control multipotent neural crest 
formation. Nature. 463(7283):958-962. 
Batsukh T, Pieper L, Koszucka AM, von Velsen N, Hoyer-Fender S, Elbracht M, Bergman 
JE, Hoefsloot LH, Pauli S. (2010) CHD8 interacts with CHD7, a protein which is mutated in 
CHARGE syndrome. Hum Mol Genet. 19(14):2858-2866.  
Bergman JE, Bosman EA, van Ravenswaaij-Arts CM, Steel KP. (2010) Study of smell and 
reproductive organs in a mouse model for CHARGE syndrome. Eur J Hum Genet. 18(2):171-
177.  
Bergman JE, Bocca G, Hoefsloot LH, Meiners LC, van Ravenswaaij-Arts CM. (2011a.) 
Anosmia predicts hypogonadotropic hypogonadism in CHARGE syndrome. J Pediatr. 
158:474–479. 
References 
 
68 
 
Bergman JE, Janssen N, Hoefsloot LH, Jongmans MC, Hofstra RM, van Ravenswaaij- Arts 
CM. (2011b) CHD7 mutations and CHARGE syndrome: the clinical implications of an 
expanding phenotype. J Med Genet. 48:334–342. 
Betancur C. (2011) Etiological heterogeneity in autism spectrum disorders: more than 100 
genetic and genomic disorders and still counting. Brain Res.1380:42-77.  
Blake KD, Davenport SL, Hall BD, Hefner MA, Pagon RA, Williams MS, Lin AE, Graham Jr 
JM. (1998) CHARGE association: an update and review for the primary pediatrician. Clin 
Pediatr (Phila). 37:159–173. 
Bosman EA, Penn AC, Ambrose JC, Kettleborough R, Stemple DL, Steel KP. (2005) Multiple 
mutations in mouse Chd7 provide models for CHARGE syndrome. Hum Mol Genet. 
14(22):3463-3476.  
Bouazoune K, Mitterweger A, Langst G, Imhof A, Akhtar A, Becker PB, Brehm A. (2002) 
The dMi-2 chromodomains are DNA binding modules important for ATP-dependent 
nucleosome mobilization. Embo J. 21:2430–2440. 
Boyer LA, Latek RR, Peterson CL. (2004) The SANT domain: a unique histone-tail-binding 
module? Nat Rev Mol Cell Biol. 5(2):158-163. 
Brehm A, Tufteland KR, Aasland R, Becker PB. (2004) The many colours of chromodomains. 
Bioessays. 26(2):133-140.  
Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C, Palleschi A, 
Pizzuti A, Grammatico P, Zampino G, Dallapiccola B, Gelb BD, Tartaglia M. (2006) Germline 
missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome 
phenotype. Am J Hum Genet. 79(1):129-135. 
Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-
Zahradnik T, König R, Kratz CP, Pantaleoni F, et al. (2010) A restricted spectrum of NRAS 
mutations causes Noonan syndrome. Nat Genet. 42(1):27-29.  
Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. (1997) Specific inhibition of Stat3 
signal transduction by PIAS3. Science. 278(5344):1803-1805. 
Cleary JO, PriceAN, Thomas DL, Scambler PJ, KyriakopoulouV,McCue K, Schneider 
JE,OrdidgeRJ, LythgoeMF. (2009) Cardiac phenotyping in ex vivo murine embryos using 
microMRI. NMR Biomed. 22:857–866. 
References 
 
69 
 
Deardorff  MA, Kaur M, Yaeger D, Rampuria A, Korolev S, Pie J, Gil-Rodríguez C, Arnedo 
M, Loeys B, Kline AD, Wilson M, Lillquist K, et al. (2007) Mutations in cohesin complex 
members SMC3 and SMC1A cause a mild variant of cornelia de Lange syndrome with 
predominant mental retardation. Am J Hum Genet. 80(3):485-494.  
Dixon J, Trainor P, Dixon MJ. (2007) Treacher Collins syndrome. Orthod Craniofac Res. 
10(2):88-95. Review. 
Dodé C, Hardelin JP. (2009) Kallmann syndrome. Eur J Hum Genet. 17(2):139-46. 
Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J, Allis CD, Chait BT, Hess JL, 
Roeder RG. (2005) Physical association and coordinate function of the H3 K4 
methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell. 121(6):873-885. 
Eberharter A, Vetter I, Ferreira R, Becker PB. (2004) ACF1 improves the effectiveness of 
nucleosome mobilization by ISWI through PHD-histone contacts. Embo J. 23:4029–4039.  
Feki A, Jefford CE, Berardi P, Wu JY, Cartier L, Krause KH, Irminger-Finger I. (2005) 
BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response 
kinase. Oncogene. 24(23):3726-3736.  
Felix TM, Hanshaw BC, Mueller R, Bitoun P, Murray JC. (2006) CHD7 gene and 
nonsyndromic cleft lip and palate. Am J Med Genet A. 140:2110–2114. 
Fischle W, Wang Y, Jacobs SA, Kim Y, Allis CD, Khorasanizadeh S. (2003) Molecular basis 
for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 
chromodomains. Genes Dev. 17:1870–1881.  
Flanagan JF, Mi LZ, Chruszcz M, Cymborowski M, Clines KL, Kim Y, Minor W, Rastinejad 
F, Khorasanizadeh S. (2005) Double chromodomains cooperate to recognize the methylated 
histone H3 tail. Nature. 438:1181–1185.  
Garrath RH, Grisham CM. (1999) Biochemistry, second edition, Figure 31.32. 
Gaspar-Maia A, Alajem A, Polesso F, Sridharan R, Mason MJ, Heidersbach A, Ramalho-
Santos J, McManus MT, Plath K, Meshorer E, Ramalho-Santos M. (2009) Chd1 regulates 
open chromatin and pluripotency of embryonic stem cells. Nature. 460(7257):863-868. 
Ge Q, Nilasena DS, O'Brien CA, Frank MB, Targoff IN. (1995) Molecular analysis of a major 
antigenic region of the 240-kD protein of Mi-2 autoantigen. J Clin Invest. 96:1730–1737.  
References 
 
70 
 
Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, 
Sun X, Jia W, Chen J, et al. (2011) Frequent mutations of chromatin remodeling genes in 
transitional cell carcinoma of the bladder. Nat Genet. 43(9):875-878. 
Hall JA, Georgel PT. (2007) CHD proteins: a diverse family with strong ties.  Biochem Cell 
Biol. 85(4):463-476. 
Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, 
Stuart RK, Ching CW, Ching KA, Antosiewicz-Bourget JE, et al. (2009) Histone 
modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 
459(7243):108-112.  
Hess JL. (2004) MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 
10:500–507. 
Ho L, Crabtree GR. (2010) Chromatin remodelling during development. Nature. 463:474–
484. 
Horsch U, Scheele A (editors). (2011) Compendium on CHARGE syndrome. Median-Verlag 
von Killisch-Horn GmbH. Heidelberg. p.11 
Hurd EA, Capers PL, Blauwkamp MN, Adams ME, Raphael Y, Poucher HK, Martin DM. 
(2007) Loss of Chd7 function in gene-trapped reporter mice is embryonic lethal and associated 
with severe defects in multiple developing tissues. Mamm Genome. 18:94–104. 
Hurd EA, Poucher HK, Cheng K, Raphael Y, Martin DM. (2010) The ATP-dependent 
chromatin remodeling enzyme CHD7 regulates pro-neural gene expression and neurogenesis 
in the inner ear. Development. 137:3139–3150. 
Ishihara K, Oshimura M, Nakao M. (2006) CTCF-dependent chromatin insulator is linked to 
epigenetic remodeling. Mol Cell. 23(5):733-742. 
Jacobs-McDaniels NL, Albertson RC. (2011) Chd7 plays a critical role in controlling left-
right symmetry during zebrafish somitogenesis. Dev Dyn. 240(10):2272-2280.  
Janssen N, Bergman JE, Swertz MA, Tranebjaerg L, Lodahl M, Schoots J, Hofstra RM, van 
Ravenswaaij-Arts CM, Hoefsloot LH. (2012) Mutation update on the CHD7 gene involved in 
CHARGE syndrome. Hum Mutat. 33(8):1149-1160.  
Jongmans MC, Admiraal RJ, van der Donk KP, Vissers LE, Baas AF, Kapusta L, van Hagen 
JM, Donnai D, de Ravel TJ, Veltman JA, Geurts van Kessel A, De Vries BB, et al. (2006) 
References 
 
71 
 
CHARGE syndrome: the phenotypic spectrum of mutations in the CHD7 gene. J Med Genet. 
43:306–314. 
Jongmans MC, Hoefsloot LH, van der Donk KP, Admiraal RJ, Magee A, van de Laar I, 
Hendriks Y, Verheij JB, Walpole I, Brunner HG, van Ravenswaaij CM. (2008) Familial 
CHARGE syndrome and the CHD7 gene: a recurrent missense mutation, intrafamilial 
recurrence and variability. Am J Med Genet A. 146A(1):43-50. 
Kalscheuer VM, Feenstra I, Van Ravenswaaij-Arts CM, Smeets DF, Menzel C, Ullmann R, 
Musante L, Ropers HH. (2008) Disruption of the TCF4 gene in a girl with mental retardation 
but without the classical Pitt-Hopkins syndrome. Am J Med Genet A. 146A(16):2053-2059. 
Kehle J, Beuchle D, Treuheit S, Christen B, Kennison JA, Bienz M, Muller J. (1998) dMi-2, a 
hunchbackinteracting protein that functions in polycomb repression. Science.  282:1897–1900.  
Kelley DE, Stokes DG, Perry RP. (1999) CHD1 interacts with SSRP1 and depends on both its 
chromodomain and its ATPase/helicase-like domain for proper association with chromatin. 
Chromosoma. 108:10–25.  
Kim J, Daniel J, Espejo A, Lake A, Krishna M, Xia L, Zhang Y, Bedford MT. (2006) Tudor, 
MBT and chromo domains gauge the degree of lysine methylation. EMBO Rep. 7:397–403. 
Kita Y, Nishiyama M, Nakayama KI. (2012) Identification of CHD7(S) as a novel splicing 
variant of CHD7 with functions similar and antagonistic to those of the full-length CHD7(L). 
Genes Cells. 17(7):536-547.  
Kobayashi M, Kishida S, Fukui A, Michiue T, Miyamoto Y, Okamoto T, Yoneda Y, 
Asashima M, Kikuchi A. (2002) Nuclear localization of Duplin, a beta-catenin-binding protein, 
is essential for its inhibitory activity on the Wnt signaling pathway. J Biol Chem. 277(8):5816-
5822.  
Krantz ID, McCallum J, DeScipio C, Kaur M, Gillis LA, Yaeger D, Jukofsky L, Wasserman 
N, Bottani A, Morris CA, Nowaczyk MJ, Toriello H, et al. (2004) Cornelia de Lange syndrome 
is caused by mutations in NIPBL, the human homolog of Drosophila melanogaster Nipped-B. 
Nat Genet. 36(6):631-635.  
Lalani SR, Safiullah AM, Molinari LM, Fernbach SD, Martin DM, Belmont JW. (2004) 
SEMA3E mutation in a patient with CHARGE syndrome. J Med Genet. 41:e94. 
Lalani SR, Safiullah AM, Fernbach SD, Harutyunyan KG, Thaller C, Peterson LE, McPherson 
JD, Gibbs RA, White LD, Hefner M, Davenport SL, Graham JM, Bacino CA, Glass NL, 
References 
 
72 
 
Towbin JA, et al. (2006) Spectrum of CHD7 mutations in 110 individuals with CHARGE 
syndrome and genotype–phenotype correlation. Am J Hum Genet. 78:303–314. 
Law ME, Templeton KL, Kitange G, Smith J, Misra A, Feuerstein BG, Jenkins RB. (2005) 
Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet 
Cytogenet. 160:1–14.  
Layman WS, McEwen DP, Beyer LA, Lalani SR, Fernbach SD, Oh E, Swaroop A, Hegg CC, 
Raphael Y, Martens JR, Martin DM. (2009) Defects in neural stem cell proliferation and 
olfaction in Chd7 deficient mice indicate a mechanism for hyposmia in human CHARGE 
syndrome. Hum Mol Genet. 18:1909–1923. 
Layman WS, Hurd EA, Martin DM. (2010) Chromodomain proteins in development: lessons 
from CHARGE syndrome. Clin Genet. 78:11–20. 
Layman WS, Hurd EA, Martin DM. (2011) Reproductive dysfunction and decreased GnRH 
neurogenesis in a mouse model of CHARGE syndrome. Hum Mol Genet. 20:3138–3150. 
Lee YW, Kim SC, Shin YL, Kim JW, Hong HS, Lee YK, Ki CS. (2009) Clinical and genetic 
analysis of the CHD7 gene in Korean patients with CHARGE syndrome. Clin Genet. 75:290–
293. 
Lemos TA, Passos DO, Nery FC, Kobarg J. (2003) Characterization of a new family of 
proteins that interact with the C-terminal region of the chromatin-remodeling factor CHD-3. 
FEBS Lett. 533:14–20. 
Lutz T, Stöger R, Nieto A. (2006) CHD6 is a DNA-dependent ATPase and localizes at nuclear 
sites of mRNA synthesis. FEBS Lett. 580(25):5851-5857.  
Marfella CG, Imbalzano AN. (2007) The Chd family of chromatin remodelers. Mutat Res. 
618(1-2):30-40.  
Marfella CG, Ohkawa Y, Coles AH, Garlick DS, Jones SN, Imbalzano AN. (2006) Mutation 
of the SNF2 family member Chd2 affects mouse development and survival. J Cell Physiol. 
209(1):162-171. 
Melicharek DJ, Ramirez LC, Singh S, Thompson R, Marenda DR. (2010) Kismet/CHD7 
regulates axon morphology, memory and locomotion in a Drosophila model of CHARGE 
syndrome. Hum Mol Genet. 19(21):4253-4264.  
Menon T, Yates JA, Bochar DA. (2010) Regulation of androgen-responsive transcription by 
the chromatin remodeling factor CHD8. Mol Endocrinol. 24(6):1165-1174. 
References 
 
73 
 
Messmer S, Franke A, Paro R. (1992) Analysis of the functional role of the Polycomb chromo 
domain in Drosophila melanogaster. Genes Dev. 6(7):1241-1254. 
Min J, Zhang Y, Xu RM. (2003) Structural basis for specific binding of Polycomb 
chromodomain to histone H3 methylated at Lys 27. Genes Dev 17:1823–1828.  
Musio A, Selicorni A, Focarelli ML, Gervasini C, Milani D, Russo S, Vezzoni P, Larizza L. 
(2006) X-linked Cornelia de Lange syndrome owing to SMC1L1 mutations. Nat Genet. 
38(5):528-530. 
Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, Matsubara Y, Arveiler 
B, Lacombe D, Pasmant E, Parfait B, Baumann C, Héron D, Sigaudy S, et al. (2007) Cardio-
facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling 
pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet. 
44(12):763-771. 
Neale BM, Kou Y, Liu L, Ma'ayan A, Samocha KE, Sabo A, Lin CF, Stevens C, Wang LS, 
Makarov V, Polak P, Yoon S, et al. (2012) Patterns and rates of exonic de novo mutations in 
autism spectrum disorders. Nature. 485(7397):242-245.  
Nishiyama M, Nakayama K, Tsunematsu R, Tsukiyama T, Kikuchi A, Nakayama KI. (2004) 
Early embryonic death in mice lacking the beta-catenin-binding protein Duplin. Mol Cell Biol. 
24(19):8386-8394.  
Nishiyama M, Oshikawa K, Tsukada Y, Nakagawa T, Iemura S, Natsume T, Fan Y, Kikuchi 
A, Skoultchi AI, Nakayama KI. (2009) CHD8 suppresses p53-mediated apoptosis through 
histone H1 recruitment during early embryogenesis. Nat Cell Biol. 11(2):172-182.  
Nishiyama M, Skoultchi AI, Nakayama KI. (2012) Histone H1 recruitment by CHD8 is 
essential for suppression of the Wnt-β-catenin signaling pathway. Mol Cell Biol. 32(2):501-
512.  
O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, Levy R, Ko A, Lee C, Smith 
JD, Turner EH, Stanaway IB, Vernot B, Malig M, Baker C, et al.  (2012) Sporadic autism 
exomes reveal a highly interconnected protein network of de novo mutations. Nature. 
485(7397):246-250.  
Pagon RA, Graham Jr JM, Zonana J, Yong SL. (1981) Coloboma, congenital heart disease, 
and choanal atresia with multiple anomalies: CHARGE association. J Pediatr. 99:223–227. 
References 
 
74 
 
Patten SA, Jacobs-McDaniels NL, Zaouter C, Drapeau P, Albertson RC, Moldovan F. (2012) 
Role of Chd7 in zebrafish: a model for CHARGE syndrome. PLoS One. 7(2):e31650.  
Pena PV, Davrazou F, Shi X, Walter KL, Verkhusha VV, Gozani O, Zhao R, Kutateladze TG. 
(2006) Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of 
ING2. Nature. 442:100–103.  
Pray-Grant MG, Daniel JA, Schieltz D, Yates JR 3rd, Grant PA. (2005) Chd1 chromodomain 
links histone H3 methylation with SAGA- and SLIK-dependent acetylation. Nature. 433:434–
438.  
Ragvin A, Valvatne H, Erdal S, Arskog V, Tufteland KR, Breen K, AM OY, Eberharter A, 
Gibson TJ, Becker PB, Aasland R. (2004) Nucleosome binding by the bromodomain and PHD 
finger of the transcriptional cofactor p300. J Mol Biol. 337:773–788.  
Randall V, McCue K, Roberts C, Kyriakopoulou V, Beddow S, Barrett AN, Vitelli F, Prescott 
K, Shaw-Smith C, Devriendt K, Bosman E, Steffes G, et al. (2009) Great vessel development 
requires biallelic expression of Chd7 and Tbx1 in pharyngeal ectoderm in mice. J Clin Invest. 
119:3301–3310. 
Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R, Kamisago M, 
Momma K, Katayama H, Nakagawa M, Fujiwara Y, Matsushima M, et al. (2007) Germline 
gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet. 39(8):1013-1017.  
Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, 
Tamburino AM, Neel BG, Kucherlapati RS. (2007) Germline gain-of-function mutations in 
SOS1 cause Noonan syndrome.  Nat Genet. 39(1):70-74. 
Rodenberg JM, Hoggatt AM, Chen M, Touw K, Jones R, Herring BP. (2010) Regulation of 
serum response factor activity and smooth muscle cell apoptosis by chromodomain helicase 
DNA-binding protein 8. Am J Physiol Cell Physiol. 299(5):C1058-1067. 
Rodríguez-Paredes M, Ceballos-Chávez M, Esteller M, García-Domínguez M, Reyes JC.  
(2009) The chromatin remodeling factor CHD8 interacts with elongating RNA polymerase II 
and controls expression of the cyclin E2 gene. Nucleic Acids Res. 37(8):2449-2460.  
Sakamoto I, Kishida S, Fukui A, Kishida M, Yamamoto H, Hino S, Michiue T, Takada S, 
Asashima M, Kikuchi A. (2000) A novel beta-catenin-binding protein inhibits beta-catenin-
dependent Tcf activation and axis formation. J Biol Chem. 275(42):32871-32878. 
References 
 
75 
 
Sanlaville D, Etchevers HC, Gonzales M, Martinovic J, Clément-Ziza M, Delezoide AL, 
Aubry MC, Pelet A, Chemouny S, Cruaud C, Audollent S, Esculpavit C, et al. (2006) 
Phenotypic spectrum of CHARGE syndrome in fetuses with CHD7 truncating mutations 
correlates with expression during human development. J Med Genet. 43(3):211-217.  
Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, Scioletti AP, Esposito 
G, Cordeddu V, Lepri F, Petrangeli V, Dentici ML, et al.  (2009) Germline BRAF mutations in 
Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated 
phenotypic spectrum. Hum Mutat. 30(4):695-702.  
Schnetz MP, Bartels CF, Shastri K, Balasubramanian D, Zentner GE, Balaji R, Zhang X, Song 
L, Wang Z, Laframboise T, Crawford GE, Scacheri PC.  (2009) Genomic distribution of 
CHD7 on chromatin tracks H3K4 methylation patterns. Genome Res. 19(4): 590–601. 
Schnetz MP, Handoko L, Akhtar-Zaidi B, Bartels CF, Pereira CF, Fisher AG, Adams DJ, 
Flicek P, Crawford GE, Laframboise T, Tesar P, Wei CL, Scacheri PC. (2010) CHD7 targets 
active gene enhancer elements to modulate ES cell-specific gene expression. PLoS Genet. 
6(7):e1001023. 
Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, 
Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, et 
al.(2006) Germline KRAS mutations cause Noonan syndrome. Nat Genet. 38(3):331-336.  
Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V. (1982) Production 
of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease 
and a subset of normal lymphoid cells. Nature. 299:65–67. 
Seelig HP, Moosbrugger I, Ehrfeld H, Fink T, Renz M, Genth E. (1995) The major 
dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional 
activation. Arthritis Rheum. 38:1389–1399.  
Seelig HP, Renz M, Targoff IN, Ge Q, Frank MB. (1996) Two forms of the major antigenic 
protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum. 39:1769–1771.  
de la Serna IL, Ohkawa Y, Imbalzano AN. (2006) Chromatin remodelling in mammalian 
differentiation: lessons from ATP-dependent remodellers. Nat Rev Genet. 7(6):461-473. 
Shi X, Hong T, Walter KL, Ewalt M, Michishita E, Hung T, Carney D, Pena P, Lan F, 
Kaadige MR, Lacoste N, Cayrou C, Davrazou F, Saha A, Cairns BR, et al. (2006) ING2 PHD 
domain links histone H3 lysine 4 methylation to active gene repression. Nature. 442:96–99.  
References 
 
76 
 
Shur I, Benayahu D. (2005) Characterization and functional analysis of CReMM, a novel 
chromodomain helicase DNA-binding protein. J Mol Biol. 352:646–655. 
Shur I, Socher R, Benayahu D. (2006) In vivo association of CReMM/CHD9 with promoters 
in osteogenic cells. J Cell Physiol. 207:374–378.  
Siebert JR, Graham Jr JM, MacDonald C. (1985) Pathologic features of the CHARGE 
association: support for involvement of the neural crest. Teratology. 31:331–336. 
Sillibourne JE, Delaval B, Redick S, Sinha M, Doxsey SJ. (2007) Chromatin remodeling 
proteins interact with pericentrin to regulate centrosome integrity. Mol Biol Cell. 18(9):3667-
3680.  
Sims RJ 3rd, Nishioka K, Reinberg D. (2003) Histone lysine methylation: a signature for 
chromatin function. Trends Genet. 19:629–639. 
 Sims RJ 3rd, Chen CF, Santos-Rosa H, Kouzarides T, Patel SS, Reinberg D. (2005) Human 
but not yeast CHD1 binds directly and selectively to histone H3 methylated at lysine 4 via its 
tandem chromodomains. J Biol Chem. 280:41789–41792.  
Sims JK, Wade PA. (2011) SnapShot: Chromatin remodeling: CHD. Cell. 144(4):626-626.e1.  
Smith CL and Peterson CL. (2005) ATP-dependent chromatin remodeling. Curr Top Dev 
Biol. 65:115–148. 
Solari F, Ahringer J. (2000) NURD-complex genes antagonise Ras-induced vulval 
development in Caenorhabditis elegans. Curr Biol.10:223–226. 
Srinivasan S, Armstrong JA, Deuring R, Dahlsveen IK, McNeill H, Tamkun JW. (2005) The 
Drosophila trithorax group protein Kismet facilitates an early step in transcriptional elongation 
by RNA Polymerase II. Development. 132(7):1623-1635. 
Srinivasan S, Dorighi KM, Tamkun JW. (2008) Drosophila kismet regulates histone H3 
lysine 27 methylation and early elongation by RNA polymerase II. PLoS Genet. 
4(10):e1000217 
Talkowski ME, Rosenfeld JA, Blumenthal I, Pillalamarri V, Chiang C, Heilbut A, Ernst C, 
Hanscom C, Rossin E, Lindgren AM, Pereira S, Ruderfer D, et al. (2012) Sequencing 
chromosomal abnormalities reveal neurodevelopmental loci that confer risk across diagnostic 
boundaries. Cell. 149(3):525-537.  
References 
 
77 
 
Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, 
Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, et al. (2001) Mutations in PTPN11, 
encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 
29(4):465-468.  
Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. (2003) CHD5, a new member of 
the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene. 
22:1002–1011. 
Thompson BA, Tremblay V, Lin G, Bochar DA. (2008) CHD8 is an ATP-dependent 
chromatin remodeling factor that regulates beta-catenin target genes. Mol Cell Biol. 
28(12):3894-3904.  
Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL. (1998) Chromatin 
deacetylation by an ATP-dependent nucleosome remodelling complex. Nature. 395:917–921. 
Tonkin ET, Wang TJ, Lisgo S, Bamshad MJ, Strachan T. (2006)  NIPBL, encoding a homolog 
of fungal Scc2-type sister chromatid cohesion proteins and fly Nipped-B, is mutated in 
Cornelia de Lange syndrome. Nat Genet. 36(6):636-641.  
Tsukiyama T. (2002) The in vivo functions of ATP-dependent chromatin-remodelling factors. 
Nat Rev Mol Cell Biol. 3(6):422-429. Review. 
Valdez BC, Henning D, So RB, Dixon J, Dixon MJ. (2004) The Treacher Collins syndrome 
(TCOF1) gene product is involved in ribosomal DNA gene transcription by interacting with 
upstream binding factor. Proc Natl Acad Sci USA. 101(29):10709-10714. 
Verloes A. (2005) Updated diagnostic criteria for CHARGE syndrome: a proposal. Am J Med 
Genet A. 133:306–308. 
Vissers LE, van Ravenswaaij CM, Admiraal R, Hurst JA, de Vries BB, Janssen IM, van der 
Vliet WA, Huys EH, de Jong PJ, Hamel BC, Schoenmakers EF, Brunner HG, et al. (2004) 
Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat 
Genet. 36(9):955-957.  
Vuorela P, La-Mello S, Saloranta C, PenttinenM, PoyhonenM,Huoponen K, Borozdin W, 
Bausch B, Botzenhart EM,Wilhelm C, Kaariainen H, Kohlhase J. (2007) Molecular analysis of 
the CHD7 gene in CHARGE syndrome: identification of 22 novel mutations and evidence for 
a low contribution of large CHD7 deletions. Genet Med. 9:690–694. 
References 
 
78 
 
Wade PA, Jones PL, Vermaak D, Wolffe AP. (1998) A multiple subunit Mi-2 histone 
deacetylase from Xenopus laevis cofractionates with an associated Snf2 superfamily ATPase. 
Curr Biol. 8:843– 846. 
Wang HB, Zhang Y. (2001) Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent 
nucleosome remodeling factor. Nucleic Acids Res. 29:2517–2521.  
Wessels K, Bohnhorst B, Luhmer I,Morlot S, Bohring A, Jonasson J, Epplen JT, Gadzicki D, 
Glaser S, Gohring G, Malzer M, Hein A, and others. (2010) Novel CHD7 mutations 
contributing to themutation spectrumin patients with CHARGE syndrome. Eur J Med Genet. 
53:280–285. 
White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, Winter C, Gregory SG, 
Hogarty MD, Maris JM, Brodeur GM. (2005) Definition and characterization of a region of 
1p36.3 consistently deleted in neuroblastoma. Oncogene. 24(16):2684-2694. 
Williams CJ, Naito T, Arco PG, Seavitt JR, Cashman SM, De Souza B, Qi X, Keables P, Von 
Andrian UH, Georgopoulos K. (2004) The chromatin remodeler Mi-2beta is required for CD4 
expression and T cell development. Immunity. 20(6):719-733. 
Williams MS. (2005) Speculations on the pathogenesis of CHARGE syndrome. Am J Med 
Genet A. 133:318–325.  
Wincent J, Holmberg E, Stromland K, Soller M, Mirzaei L, Djureinovic T, Robinson KL, 
Anderlid BM, Schoumans J. (2008) CHD7 mutation spectrum in 28 Swedish patients 
diagnosed with CHARGE syndrome. Clin Genet. 74:31–38. 
Wolffe AP. (1992) New insights into chromatin function in transcriptional control. FASEB J. 
6(15):3354-3361. Review. 
Woodage T, Basrai MA, Baxevanis AD, Hieter P, Collins FS. (1997) Characterization of the 
CHD family of proteins. Proc Natl Acad Sci U S A. 94(21):11472-11477. 
Wysocka J, Myers MP, Laherty CD, Eisenman RN, Herr W. (2003) Human Sin3 deacetylase 
and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together 
selectively by the cell-proliferation factor HCF-1. Genes Dev. 17: 896–911. 
Xue Y, Wong J, Moreno GT, Young MK, Cote J, Wang W. (1998) NURD, a novel complex 
with both ATP dependent chromatin-remodeling and histone deacetylase activities. Mol Cell. 
2:851–861. 
References 
 
79 
 
Yates JA, Menon T, Thompson BA, Bochar DA. (2010) Regulation of HOXA2 gene 
expression by the ATP-dependent chromatin remodeling enzyme CHD8. FEBS Lett. 
584(4):689-693.  
Yoshida T, Hazan I, Zhang J, Ng SY, Naito T, Snippert HJ, Heller EJ, Qi X, Lawton LN, 
Williams CJ, Georgopoulos K. (2008) The role of the chromatin remodeler Mi-2β in 
hematopoietic stem cell self renewal and multilineage differentiation. Genes Dev. 22:1174–
1189. 
Yuan CC, Zhao X, Florens L, Swanson SK, Washburn MP, Hernandez N. (2007) CHD8 
associates with human Staf and contributes to efficient U6 RNA polymerase III transcription. 
Mol Cell Biol. 27(24):8729-8738.  
Zahir F, Firth HV, Baross A, Delaney AD, Eydoux P, Gibson WT, Langlois S, Martin H, 
Willatt L, Marra MA, Friedman JM. (2007) Novel deletions of 14q11.2 associated with 
developmental delay, cognitive impairment and similar minor anomalies in three children. J 
Med Genet. 44(9):556-561.  
Zenker M, Voss E, Reis A. (2007) Mild variable Noonan syndrome in a family with a novel 
PTPN11 mutation. Eur J Med Genet. 50(1):43-47.  
Zentner GE, Hurd EA, Schnetz MP, Handoko L, Wang C, Wang Z, Wei C, Tesar PJ, 
Hatzoglou M, Martin DM, Scacheri PC. (2010) CHD7 functions in the nucleolus as a positive 
regulator of ribosomal RNA biogenesis. Hum Mol Genet. 19(18):3491-3501.  
Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. (1998) The dermatomyositis-specific 
autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome 
remodeling activities. Cell. 95:279–289.  
 
Abbreviations 
 
80 
 
6. Abbreviations 
aa                                                 amino acid 
ASD     Autism Spectrum Disorder 
ASH1      Absent, Small or Homeotic 1 
ATP      adenosintriphosphate 
BAF     Brahma associated factor complex  
BiFC      bimolecular fluorescence complementation 
bp      base pair 
BSA     bovine serum albumin 
BRK     Brahma and Kismet domain 
°C      degree Celsius 
cDNA     complementary DNA 
Co-IP     co-immunoprecipitation 
CHD     chromodomain helicase DNA-binding 
ChIP-chip     chromatin immunoprecipitation ("ChIP") with 
microarray technology ("chip") 
Chromo    chromatin organization modifier 
COBALT    Constraint-based Multiple alignment tool 
CR     conserved region 
Ctcf     11-zinc finger protein or CCCTC-binding factor 
Cy3     indocarbocyanine 
DAB     3,3´-diaminobenzidine tetrahydrochloride 
DAPI      diamidino-2-phenylindole dihydrochloride 
dATP      desoxyriboadenosintriphosphate 
DMEM     Dulbecco’s modified Eagle’s medium 
DNA      deoxyribonucleic acid 
DNAse     deoxyribonuclease 
DPBS      Dulbecco's phosphate buffered saline 
dpc     days post coitum     
Duplin     for axis duplication inhibitor 
EDTA     ethylene diamine tetra-acetic acid 
EGFP      enhanced green fluorescent protein 
ESC     embryonic stem cell 
et al.      et alii (and others) 
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FAM124B     Family with sequence similarity 124B 
FBS     fetal bovine serum 
Fig.      Figure 
FITC      fluorescein isothiocyanate 
Gapdh     glyceraldehyde-3-phosphate dehydrogenase gene 
HEPES     N-(-hydroxymethyl) piperazin, N’-3-propanesulfoneacid 
HPLC     High-performance liquid chromatography 
Hprt      hypoxanthine guanine phosphoribosyl transferase  gene 
HRP     horseradish peroxidase 
IgG      immunoglobulin G 
ICC     immunocytochemistry 
IHC     immunohistochemistry 
IHH      idiopathic hypogonadotropic hypogonadism 
IPTG      Isopropyl-ß-thiogalactopyranoside 
ISH     In situ hybridization 
kb      kilobase pairs 
kDa      kilodalton 
LC     liquid-chromatography 
min      minute 
ml      milliliter 
MLL     mixed lineage leukemia 
MLPA     Multiplex Ligation-dependent Probe Amplification 
MRCV-CV1    human fibroblast cell line 
MO     morpholino 
mRNA     messenger RNA 
MS     mass spectrometry 
NCBI      national center for biotechnology information 
NDD     neurodevelopmental disorders 
ng      nanogram 
NIH3T3     mouse embryonic fibroblast cell line 
NuRD     nucleosome remodeling and deacetylase 
PAGE     polyacrylamide gel electrophoresis 
PBAF      Polybromo containing complex 
PBS     Phosphate Buffered Saline 
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PCR      polymerase chain reaction 
PFA     paraformaldehyde 
pH     preponderance of hydrogen ions 
PHD     plant homeo domain 
PLA     proximity ligation assay 
rDNA     ribosomal DNA 
RNA     ribonucleic acid 
rpm     rotation per minute 
RT      room temperature 
RT-PCR     reverse transcriptase-PCR 
SANT     Switching-defective protein 3, Adaptor 2, Nuclear 
receptor corepressor, Transcription factor IIIB 
Sdha     succinate dehydrogenase complex, subunit A 
SDS      sodium dodecylsulfate 
SILAC    stable isotope labeling by amino acids in cell culture 
SMC     smooth muscle cell 
SNF2     sucrose non-fermenting 2 
Taq DNA polymerase   Thermus aquaticus DNA polymerase 
TPBS     Phosphate Buffered Saline with Tween-20 
Tcf     T-cell factor 
TCS     Treacher Collins syndrome 
TE      Tris-EDTA buffer 
Tris      trihydroxymethylaminomethane 
TRX     trithorax 
UTR      untranslated region 
WAR     WDR5, ASH2L and RbBP5 
WT      wild-type 
X-α-gal     5-bromo-4-chloro-3-indolyl-α-D-galactopyranoside 
Y2H     yeast two hybrid 
μg      microgram 
μl      microliter 
 
The names of nucleic/amino acids are abbreviated in accordance with internationally 
accepted codes. 
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